ВНУТРИМОЛЕКУЛЯРНЫЕ СОЕДИНЕНИЯ ТРИГЛИЦЕРИДОВ ЖИРНЫХ КИСЛОТ

Изобретение относится к продукту, используемому в шоколаде, маргарине или шортенинге, полученному плавлением смеси компонентов (а) и (b), где компонент (а) содержит триглицерид динасыщенных среднецепочечных жирных кислот и мононасыщенной длинноцепочечной жирной кислоты и (b) содержит триглицерид 1,3-динасыщенных длинноцепочечных жирных кислот и 2-мононенасыщенной длинноцепочечной жирной кислоты, причем длина связи, определенная рентгенодифракцией, измеренная у продукта, составляет 65 Å или более, причем среднецепочечная жирная кислота(ы) имеет от 6 до 12 атомов углерода, и длинноцепочечная жирная кислота(ы) имеет от 14 до 24 атомов углерода. Благодаря образованию внутримолекулярных соединений жиры и масла содержат большое количество симметричных триглицеридов, таких как какао-масло, и содержат среднецепочечные жирные кислоты, не образующие отдельные кристаллы, и, кроме того, могут придавать продукту гладкую текстуру и предотвращать помутнение. 7 з.п. ф-лы, 9 ил., 17 табл.

NATURSTOFFE UND DEREN DERIVATE ZUR PRÄVENTION UND BEHANDLUNG VON HERZKREISLAUF-, LEBER- UND NIERENERKRANKUNGEN UND FÜR KOSMETISCHE ANWENDUNGEN

COIX SEED OIL COMPRISING 11 TRIGLYCERIDES, FORMULATION AND APPLICATION THEREOF

COIX SEED OIL COMPRISING 11 TRIGLYCERIDES, FORMULATION AND APPLICATION THEREOF

COIX SEED OIL COMPRISING 11 TRIGLYCERIDES, FORMULATION AND APPLICATION THEREOF

PROCEDURE FOR THE PRODUCTION OF LIPOPROTEINEN, LIPOAMINOSÄUREN, LIPIDESTERN, AND GLUCOLIPIDEN OUT IN OLIVE OIL CONTAINED FATTY ACIDS

OLEATE MONO ESTER FROM ESTROGENEN TO THE TREATMENT OF OBESITY

APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT AND RELATED PRODUCTS THEREOF

The present application relates to extracting, from a traditional Chinese medicine, a plurality of compounds capable of prompting nucleic acid delivery or synthetic compounds, and promoting nucleic acid such as sRNA to absorb and enter a target cell using the extracted compounds or a plurality of combinations and promoting the nucleic acid to enter required target sites in vivo of an object.

COMPOSITION AND METHOD FOR TREATING UREA

The present disclosure provides a composition for treating urea particles under ambient atmospheric conditions, a method for treating urea particles with the composition and to a fertiliser treated with the composition. The composition functions to reduce moisture induced agglomeration of treated urea particles compared to moisture induced agglomeration of untreated urea particles. The composition includes a solvent and a mixture of a first and a second aliphatic compound, each compound respectively comprising a selected C8-C14 saturated straight chain hydrocarbon a selected C15-C19 saturated straight chain hydrocarbon.

COIX SEED OIL COMPRISING 11 TRIGLYCERIDES, FORMULATION AND APPLICATION THEREOF

A coix seed oil comprising 13 triglycerides extracted from coix seeds, formulation and application thereof. Specifically, the coix seed oil comprises the following 11 triglyceride components (calculated by mass percentage): glyceryl trilinoleate (4.87-6.99%), glyceryl 1-oleate-2,3-dilinoleate (13.00-18.69%), glyceryl 1-palmitate-2,3-dilinoleate (5.25-7.54%), glyceryl1,3-dioleate-2-linoleate (13.23-19.02%), glyceryl 1-palmitate-2-linoleate-3-oleate (10.26-14.75%), glyceryl 1,3-dipalmitate-2-linoleate (2.28-3.28%), glyceryl trioleate (14.44-20.76%), glyceryl 1-palmitate-2,3-dioleate (8.06-11.58%), glyceryl 1-oleate-2-linoleate-3-stearate (1.37-1.97%), glyceryl 1,3-dipalmitate-2-oleate (1.52-2.19%), and 1,2-dioleate-3-stearate (1.29-1.86%). The coix seed oil can be used in the preparation of anti-tumour medicine.

NOVEL HIGH VISCOSITY LIQUID BENZOATE ESTER COMPOSITIONS AND POLYMER COMPOSITIONS CONTAINING SAID ESTER COMPOSITIONS

Ester compositions based on blends of the mono- and dibenzoates of 2,2,4-trimethyl-1,3-pentanediol and containing a minimum of 87 weight percent of the dibenzoate are novel and exhibit viscosities that are unexpectedly high relative to the benzoates of other mono-and polyfunctional alcohols. These viscosities are not exhibited at lower concentrations of the dibenzoate.

Verfahren zur Herstellung eines neuen Stearinsäurepolyglykolesters.

Verfahren zur Herstellung eines neuen Ölsäurepolyglykolesters.

Verfahren zur Herstellung eines neuen Stearinsäurepolyglykolesters.

Verfahren zur Herstellung eines neuen Polyglykolesters.

SEEDS OIL S TEARS, CONTAINING 11 TRIGLYCERIDES, AND ITS PHARMACEUTICAL PREPARATION AND ITS APPLICATION

Manufactoring process of esters

PREPARING MONOESTERS UNSATURATED OXIDIZING CATALYTIC CARBONYLATION OF DIOLEFINS

고도 불포화 지방산 에틸 에스터의 신규한 생산 방법

... 본 발명은 은염 수용액을 사용하여 고도 불포화 지방산 및/또는 이의 유도체의 생산/정제시에 은염 수용액의 열화를 억제하면서 고도 불포화 지방산 및/또는 이의 유도체를 생산/정제하는 방법을 제공한다. 본 발명은 또한 고도 불포화 지방산 및/또는 이의 유도체를 포함하는 혼합물로부터 고도 불포화 지방산 및/또는 이의 유도체를 정제하는 방법에서, 10 이하의 과산물가(POV)를 가진 혼합물을 은염 수용액과 접촉하거나 혼합한다.

METHOD FOR PRODUCING FATTY ACID POLYOXYETHYLENE METHYL ETHER

A method for producing a fatty acid polyoxyethylene methyl ether in which ethylene oxide is added to a fatty acid methyl ester component comprising, as a main component, a fatty acid methyl ester having a fatty acid residue of 18 to 22 carbon atoms, the addition being conducted in the presence of a composite metal oxide catalyst and at least one alcohol selected from the group consisting of diethylene glycol, ethylene glycol, propylene glycol, ethanol, methanol and isopropyl alcohol.

NOVEL COMPOUNDS

PREPARATION OF UNSATURATED MONOESTERS BY CATALYTIC OXIDATIVE CARBONYLATION OF DIOLEFINS

HYDROPHILIERUNG OF POLYOLEFIN AND/OR POLYESTER CONTAINING MATERIALS

Free-polyunsaturated-fatty-acid-containing composition and method for manufacturing same

Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is at least 80.0% of the amount of fatty acids in the composition; and a method for manufacturing a free-polyunsaturated-fatty-acid-containing composition, comprising: providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms; performing a hydrolysis treatment on a reaction solution prepared by combining the provided raw material composition, a lower alcohol, water having a total metal content of 0.01 ppm or less, and an alkali catalyst; and limiting the contact between the reaction composition and the metal after the hydrolysis treatment so that the product T [cm2 x days] of the contact surface area [cm2 ] per 1 g and the contact time [days] between the composition and the metal is 100 or less.

NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND

Provided are: a novel nanoparticle; a contrast agent for magnetic resonance imaging comprising the same; and a zwitterionic ligand compound to be used in the production of the nanoparticle. The contrast agent for MRI according to the present invention is appropriately usable as a contrast agent for MRI in the medical field. The nanoparticle and zwitterionic ligand compound according to the present invention are applicable to various pharmaceutical compositions, etc. including a contrast agent for MRI, and broadly usable in, for example, various diagnostic methods and test reagents in the fields of pharmaceuticals, bioengineering, etc.

FREE POLYUNSATURATED FATTY ACID-CONTAINING COMPOSITION AND MANUFACTURING METHOD THEREFOR

The present invention is: a free polyunsaturated fatty acid-containing composition, which comprises at least one C20 or higher free polyunsaturated fatty acid, the content being at least 80.0% of the fatty acids in the composition, and satisfies at least one selected from a group consisting of conditions (1) and (2): (1) the content of conjugated unsaturated fatty acid is 1.0% or less of the fatty acids in the composition, and (2) the Gardner color is less than 3+; and a manufacturing method for the free polyunsaturated fatty acid-containing composition comprising the preparation of a feedstock composition containing at least one C20 or higher polyunsaturated fatty acid, and hydrolysis of a reaction solution containing the prepared feedstock composition, a lower alcohol, water and an alkali catalyst at a temperature of 10°C or lower.

CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.

Method of preparation of esters arylic of carboxylic acids

New monoesters and proceeded of preparation

METHOD OF PREPARING LIPOPROTEINS, LIPOAMINOACIDS, LIPID ESTERS, AND GLUCOLIPIDS FROM OLIVE OIL AND/OR ITS CONSTITUENTS WHICH ARE CONDENSED WITH VEGETAL PROTEIN HYDROLYSATES OR AMINOACIDS OR ESTERIFICATED WITH FATTY ALCOHOLS OR SUGARS

A method of preparing lipoproteins, lipoaminoacids, lipid esters, and glucolipids from olive oil or one or more of its constituting fatty acids which are condensed with vegetal protein hydrolysates or aminoacids or esterificated with alcohols or sugars, said fatty acids being chlorinated fatty acids of the olive oil.

ENZYME INHIBITORS

A compound of Formula (I) wherein R is a biomolecular residue, or derivative thereof, of a C-terminal amide biomolecule which is activated by the action of PAM; and X is O or CH2 or a salt, or prodrug thereof.

ОФТАЛЬМОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ

Изобретение относится к новым офтальмологическим композициям, в частности к офтальмологической композиции, содержащей соединение формулы (I), где значения для групп Rи Rприведены в формуле изобретения, и офтальмологически приемлемый носитель. Изобретение также относится к способу лечения сухости глаз, включающему локальное введение в глаза субъекта, нуждающегося в этом, терапевтически эффективного количества указанной офтальмологической композиции.10 н. и 10 з.п. ф-лы, 6 ил., 6 пр.

СОКРИСТАЛЛЫ МОДУЛЯТОРОВ РЕГУЛЯТОРА ТРАНСМЕМБРАННОЙ ПРОВОДИМОСТИ ПРИ КИСТОЗНОМ ФИБРОЗЕ

PROCESS FOR PREPARING PHENOLATED FATTY ACID ESTERS

... 1346530 Preparation of phenolated fatty acid esters KAO SOAP CO Ltd 11 Dec 1972 [17 Dec 1971] 57064/72 Heading C2C Phenolated fatty acid esters containing principally the p-substitution product are prepared by reacting conjugated unsaturated fatty acid ester with phenol at an elevated temperature in the presence of acidic catalyst. The conjugated unsaturated fatty acid ester may be one of an unsaturated fatty acid having 10-24 carbon atoms and having two or more double bonds at least two of which are conjugated and alcohols of the formula ROH where R is alkyl having 1 to 8 carbon atoms and mixtures of the said ester. In an example methyl linoleate is reacted with phenol.

Functional fluid

NEW CONNECTIONS

PREPARATION OF ESTERIFIED PROPOXYLATED GLYCERIN FROM FREE FATTY ACIDS

A novel method is provided for the preparation of a esterified propoxylated glycerin having food grade quality by reacting at temperatures of from about 100.degree.C to about 250.degree.C a propoxylated glycerin having from 2 to 100 oxypropylene oxide units per glycerin with excess C10 - C24 fatty acids and purifying the reactant product by methanol extraction or steam stripping and neutralization of excess fatty acid.

PREPARATION OF UNSATURATED MONOESTERS BY THE CATALYTIC OXIDATIVE CARBONYLATION OF DIOLEFINS

METHOD OF MANUFACTURING BIO-DIESEL AND REACTOR

A reactor and process for the production of bio-diesel. The reactor includes one or more coiled reaction lines. The lines are positioned within a tank containing a heat transfer media such as molten salt, maintained at about 750° F. A pump circulates the media within the tank. An emulsion of alcohol; refined feed stock, including glycerides and/or fatty acids; and preferably water is pumped through the reaction lines at temperatures and pressures sufficient to maintain the alcohol in a super-critical state. The curvature of the coils, pump pulsing, and the flow rate of the emulsion keep the emulsion in a turbulent state while in the reactor, ensuring thorough mixing of the alcohol and feed stock. The alcohol reacts with the glycerides and fatty acids to form bio-diesel. The reaction is fast, efficient with regard to energy input and waste generation, and requires minimal alcohol.

Cinnamyl alcohol fatty acid ester derivative and application and preparation method thereof

Preparation method of isooctyl polyoxypropylene aliphatic ester

POLY-UNSATURATED FATTY ACID ESTER COMPOSITION AND ITS PREPARATION

NEW CLASS OF CATIONIC LIPIDS FOR TRANSPORTING ACTIVE AGENTS INTO CELLS

PROCESSO PARA DESIDROXILACAO DE ESTERES DE CADEIA CURTA

Natural deodorant compositions comprising renewably-based, biodegradable 1,3-propanediol

Disclosed herein are all natural or substantially natural deodorant and antiperspirant compositions comprising 1,3-propanediol wherein the 1,3-propanediol in said all natural or substantially natural deodorant or antiperspirant composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein upon biodegradation, the biologically-derived 1,3-propanediol contributes no anthropogenic CO₂ emissions to the atmosphere.

NATURAL COMPOUNDS AND DERIVATIVES THEREOF FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR, HEPATIC AND RENAL DISEASES AND FOR COSMETIC APPLICATIONS

The present invention refers to the use of phenolic compounds and their derivatives represented by formula I wherein R1 and R2 are selected from among: OH, OCOalkyl, or OCOalkenyl, and R3 is either H, OH, OCOalkyl or OCOalkenyl, wherein the alkyl or alkenyl chains present from 2 to 22 carbon atoms and wherein at least one OCOalkyl or OCOalkenyl group is present in the structure, for the prevention and treatment of cardiovascular, hepatic or renal diseases, as well as to their cosmetic applications, to compositions that include these compounds and to some novel phenolic compounds and derivatives.

Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight

The estrogen is selected from the group consisting of estrone, diethylstilbestrol, estriol, estradiol and ethinyl estradiol; the fatty acid is selected from the group consisting of oleic, linoleic, linolenic, stearic, palmitic, palmitoleic and arachidonic acids. They mimic the function of estrone monooleate, as a signal that informs the brain of the size of fat tissue mass. Preferred compositions for intravenous injection comprise the monoester incorporated in a lipidic suspension, prepared from lipoproteins or from liposome components such a soy oil and egg phospolipids. When administered to rats with a 15% of total adipose tissue, they produce weight reduction of about 10%, by a new and unexpected mechanism. They are useful for the treatment of obesity and/or overweight in mammals, with the advantages of high efficacy and low toxicity.

NATURAL SUBSTANCES AND THEIR DERIVATIVES FOR THE PREVENTION AND TREATMENT OF HEART CYCLE, LIVER AND KIDNEY ILLNESSES AND FOR COSMETIC APPLICATIONS

Free-polyunsaturated-fatty-acid-containing composition and method for manufacturing same

Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is at least 80.0% of the amount of fatty acids in the composition; and a method for manufacturing a free-polyunsaturated-fatty-acid-containing composition, comprising: providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms; performing a hydrolysis treatment on a reaction solution prepared by combining the provided raw material composition, a lower alcohol, water having a total metal content of 0.01 ppm or less, and an alkali catalyst; and limiting the contact between the reaction composition and the metal after the hydrolysis treatment so that the product T [cm2 x days] of the contact surface area [cm2 ] per 1 g and the contact time [days] between the composition and the metal is 100 or less.

Process for the treatment of an ion exchange resin

A process for the reactivation of an acidic ion exchange resin is described. The invention relates to the treatment of an at least partially deactivated resin which has been deactivated by contact with an impure ethylenically unsaturated acid or ester containing target impurities. The reactivation includes the step of contacting the at least partially deactivated resin with an alcohol to thereby increase the activity thereof. The invention extends to reactivating a resin deactivated by contact with an impure ethylenically unsaturated acid, ester or nitrile containing target impurities by contacting the at least partially deactivated resin with an alcohol and a carboxylic acid to thereby increase the activity thereof. A reactivated resin and a process for preparing and purifying an ethylenically unsaturated acid or ester of the following formula:- R-C(=(CH) ) -COOR are also described.

Coix seed oil comprising 11 triglycerides, formulation and application thereof

A coix seed oil comprising 13 triglycerides extracted from coix seeds, formulation and application thereof. Specifically, the coix seed oil comprises the following 11 triglyceride components (calculated by mass percentage): glyceryl trilinoleate (4.87-6.99%), glyceryl 1-oleate-2,3-dilinoleate (13.00-18.69%), glyceryl 1-palmitate-2,3-dilinoleate (5.25-7.54%), glyceryl1,3-dioleate-2-linoleate (13.23-19.02%), glyceryl 1-palmitate-2-linoleate-3-oleate (10.26-14.75%), glyceryl 1,3-dipalmitate-2-linoleate (2.28-3.28%), glyceryl trioleate (14.44-20.76%), glyceryl 1-palmitate-2,3-dioleate (8.06-11.58%), glyceryl 1-oleate-2-linoleate-3-stearate (1.37-1.97%), glyceryl 1,3-dipalmitate-2-oleate (1.52-2.19%), and 1,2-dioleate-3-stearate (1.29-1.86%). The coix seed oil can be used in the preparation of anti-tumour medicine.

NATURAL COMPOUNDS AND THEIR DERIVATIVES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR, HEPATIC AND RENAL DISEASES AND FOR COSMETIC APPLICATIONS

The present invention refers to the use of phenolic compounds and their derivatives represented by formula I wherein R1 and R2 are selected from among: OH, OCOalkyl, or OCOalkenyl, and R3 is either H, OH, OCOalkyl or OCOalkenyl, wherein the alkyl or alkenyl chains present from 2 to 22 carbon atoms and wherein at least one OCOalkyl or OCOalkenyl group is present in the structure, for the prevention and treatment of cardiovascular, hepatic or renal diseases, as well as to their cosmetic applications, to compositions that include these compounds and to some novel phenolic compounds and derivatives. (see formula I) ...

LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

OPHTHALMIC FORMULATION

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R1 is a linear or branched C9-C33 alkyl or a linear or branched C9-C33 alkenyl with 1 to 4 double bonds; R2 is a linear or branched C9-C19 alkyl or a linear or branched C9-C19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Procédé de fractionnement d'un mélange d'esters d'acides gras

L'invention concerne un procédé de fractionnement d'un mélange d'esters d'acides gras en vue de séparer les esters ayant des degrés d'insaturation différents. Le procédé consiste a à déposer directement le mélange d'esters dans un lit de résine échangeuse d'ions fortement acide, permutée sous forme Ag**+, bà amener ensuite un solvant à base de méthanol à percoler le lit de résine en vue d'éluer les esters saturés et mono-insaturés, c le cas échéant à amener un solvant à base d'éthanol à percoler le lit de résine en vue de décrocher et d'éluer les esters di-insaturés, d à utiliser ensuite un solvant d'élution finale comportant un nitrile ou un alcène ou un alcyne, de type aliphatique, et à amener ce solvant à percoler le lit de résine en vue de décrocher et d'éluer les esters restants, e et à extraire les esters contenus dans chacun des solvants, notamment par évaporation du solvant concerné. L'invention peut en particulier être appliquée pour séparer des mélanges d'esters méthyliques provenant ...

COMPOSITIONS COMPRISING MONO AND DI ESTERS OF BIOLOGICALLY-BASED 1.3-PROPANEDIOL

Compositions comprising esters of 1,3-propanediol are provided. The 1,3- propanediol used to form the esters is biologically derived. The esters can have at least 3% biobased carbon. The compositions can further comprise biologically-derived 1,3- propanediol. Also provided are processes for producing compositions comprising esters of 1,3-propanediol. The processes include providing biologically produced 1,3-propanediol, contacting the 1,3-propanediol with an organic acid, which produces an ester, and recovering the produced ester.

Compositions and methods of antiallergic phorbol ester and phorbol derivatives as the main active ingredients from the seeds of aquilaria malaccensis

The present invention relates to phorbol esters from the seeds of Aquilaria malaccensis by a series of chromatographic processes, and compositions containing these congeners for the treatment of allergic responses.

Prepn. of pure spatial isomers of mono:glyceride(s) - by enzymatic esterification of glycerol adsorbed on solid carrier for mono:glyceride sulphate prepn. as surfactant for food, cosmetics and pharmaceuticals

... (i) Pure spatially isomeric monoglycerides of formula RCOOCH2CHOHCH2OH (I), (ii) mixts. of monoglycerides (R = C9H19, C11H23, C13H27, C15H31, C17H35), (iii) mixts. of monoglyceride sulphates of formula RCOOCH2CHOCH2OSO3Na (II), and (iv) new materials comprising glycerol adsorbed on a solid carrier comprising SiO2 gel (30-70 mesh; 70-230 mesh; 230-400 mesh), 'Florisil' (RTM, 'Chromosorb' (WHP:WAW) (RTM), 'Volaspher' (RTM), 'Celite'; (535;545) (RTM), active C, porous glass beads (345 A; 810 A), Al2O3 (neutral; basic), cellulose, triacetylcellulose, or starch, are claimed. R = straight-chain, (un)satd. 7-21C aliphatic gp., opt. icnluding X gp(s). or to which a Y gp. is linked; X = C=O, -C-O-, C=S, -C-S-, -C=C-, or -C=C-; Y = F, Cl, Br, I, (CF2)nCF3, or (CH2)nCH3; n = 0-20. USE/ADVANTAGE - (I) are used for direct conversion to (II) (claimed). (I) are nonionic surfactants, and raw materials for anionic tensides, and raw materials for components for biologically active natrual and other substances ...

NATURAL COMPOUNDS AND DERIVATIVES THEREOF FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR, HEPATIC AND RENAL DISEASES AND FOR COSMETIC APPLICATIONS

Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications

PREPARING MONOESTERS UNSATURATED OXIDIZING CATALYTIC CARBONYLATION OF DIOLEFINS

fluido funcional, produto de limpeza ou produto para o cuidado pessoal, e método de fabricação de um produto de limpeza ou produto para o cuidado pessoal

NOVEL COMPOUNDS

СПОСОБ ОБРАБОТКИ ИОНООБМЕННОЙ СМОЛЫ

Группа изобретений предназначена для использования в области регенерации ионообменных смол, дезактивация которых произошла в результате контакта с загрязненной ненасыщенной кислотой или эфиром с двойной связью, или в результате контакта с загрязненной ненасыщенной кислотой, эфиром или нитрилом с двойной связью, содержащими загрязняющие примеси. Варианты способов регенерации включают введение в контакт хотя бы частично дезактивированной смолы со спиртом или со спиртом и карбоновой кислотой для увеличения активности смолы. Способы регенерации кислотной ионообменной смолы, регенерированная смола и способ получения и очистки ненасыщенной кислоты или эфира с двойной связью формулы: R-C(=(CH))-COOR, где Rи Rявляются водородом или алкильной группой, содержащей 1-12 атомов углерода, а m=1, обеспечивают многократную регенерацию без потери активности смолы, что позволяет длительно и эффективно использовать смолу в непрерывных или полунепрерывных процессах. 5 н. и 12 з.п. ф-лы, 1 ил., 9 табл., 10 ...

СПОСОБ ОБРАБОТКИ ИОНООБМЕННОЙ СМОЛЫ

... 1. Способ регенерации кислотной ионообменной смолы, которая была хотя бы частично дезактивирована в результате контакта с загрязненной ненасыщенной кислотой или эфиром с двойной связью, содержащими целевые загрязняющие примеси, включающий стадию:введения в контакт хотя бы частично дезактивированной смолы с C-Cалифатическим алканолом для повышения активности смолы.2. Способ регенерации кислотной ионообменной смолы, которая была хотя бы частично дезактивирована в результате контакта с загрязненной ненасыщенной кислотой, эфиром или нитрилом с двойной связью, содержащими целевые загрязняющие примеси, включающий стадии:введения в контакт хотя бы частично дезактивированной смолы с C-Cалифатическим алканолом и карбоновой кислотой для повышения активности смолы.3. Способ регенерации кислотной ионообменной смолы по п.1 или 2, где кислотная ионообменная смола находится в форме уложенного слоя смолы.4. Способ регенерации кислотной ионообменной смолы по п.1 или 2, где слой смолы регенерируют способом ...

СПОСОБ ПОЛУЧЕНИЯ ПРОДУКТА НА ОСНОВЕ РАСТИТЕЛЬНОГО МАСЛА

... 1. Состав, подходящий для получения стильбенов, отличающийся тем, что он содержит сложные эфиры пиносильвина или производных пиносильвина и обогащен по отношению к ним. ! 2. Состав по п.1, отличающийся тем, что процентное содержание сложного эфира пиносильвина или производного пиносильвина в составе составляет по меньшей мере около 3 мас.%, например, около 3-80 мас.%, предпочтительно около 5-50 мас.%, от общей массы состава. ! 3. Состав по п.1, отличающийся тем, что он содержит сложные эфиры пиносильвина или простого монометилового эфира пиносильвина, кислотный остаток которых образован жирной кислотой или смоляной кислотой. ! 4. Состав по п.3, отличающийся тем, что кислотный остаток сложных эфиров образован карбоновой кислотой, содержит неразветвленную углеводородную структуру, образованную 16-24 атомами углеродами, которые полностью насыщенны или содержат 1-3 двойные связи. ! 5. Состав по п.4, отличающийся тем, что кислотный остаток сложных эфиров образован линолевой, линоленовой или ...

Method of alkene metathesis

Catalyst and process

POLY-UNSATURATED FATTY ACID ESTER COMPOSITION AND ITS PREPARATION

... 1,240,513. Fatty acid esters. ONO PHARMACEUTICAL CO. Ltd. 13 Sept., 1968, No. 43790/68. Heading C2C. [Also in Division A5] Mixtures of at least 30% methyl or ethyl esters of -linolenic acid and not more than 70% methyl or ethyl esters of linoleic acid are prepared by heating a solution of a raw material containing -linolenic acid or its methyl or ethyl ester with urea, filtering and recovering the ester composition from the filtrate or alternatively by passing through a column of silver adsorbed on a carrier, eluting with a solvent and collecting the enriched eluate. The raw materials may be mixtures of fatty acids containing -linolenic acid or the methyl and ethyl esters or oils from plant seeds, e.g. Oenothera homarkiana or Symphytum officinale or from microbes or protozoa. The compositions are suitable for the treatment of diseases accompanied by abnormal liver metabolism.

Free-polyunsaturated-fatty-acid-containing composition and method for manufacturing same

Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is at least 80.0% of the amount of fatty acids in the composition; and a method for manufacturing a free-polyunsaturated-fatty-acid-containing composition, comprising: providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms; implementing a hydrolysis treatment on a reaction solution prepared by combining the provided raw material composition, a lower alcohol, water having a total metal content of 0.01 ppm or less, and an alkali catalyst; and limiting the contact between the reaction composition and the metal after the hydrolysis treatment so that the product T [cm ...

Nanoparticle, contrast agent for magnetic resonance imaging comprising same and zwitterionic ligand compound

Provided are: a novel nanoparticle; a contrast agent for magnetic resonance imaging comprising the same; and a zwitterionic ligand compound to be used in the production of the nanoparticle. The contrast agent for MRI according to the present invention is appropriately usable as a contrast agent for MRI in the medical field. The nanoparticle and zwitterionic ligand compound according to the present invention are applicable to various pharmaceutical compositions, etc. including a contrast agent for MRI, and broadly usable in, for example, various diagnostic methods and test reagents in the fields of pharmaceuticals, bioengineering, etc.

METHOD FOR FRACTIONATING A MIXTURE OF ESTERS OF FATTY ACIDS

PREPARATION DE MONOESTERS NON-SATURES PAR CARBONYLATION CATALYTIQUE OXYDANTE DE DIOLEFINES

Novel Alpha-Hydroxy Carboxylic Acid And Derivatives And Other GRAS- Based Prodrugs Of Gamma-Hydroxybutyrate (GHB) And Uses Thereof

The invention describes pharmaceutical compounds and compositions comprised of prodrug ligands attached to GHB (CNS drugs) in a manner that substantially decreases or deters the potential for GHB abuse, illicit and illegal use, and overdose. These compounds and compositions may provide substantially higher bioavailability, substantially higher half-life, substantially higher chemical and biological stability, and easier shipping and distribution requirements. These GHB prodrug compounds may alter both the physical and chemical properties and thus may not be suitable for illicit use as a date-rape drug (i.e., they may not dissolve instantly in water based drinks, may have different color once in solution, and/or may have a taste and odor once in solution etc.). When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent GHB.

Plant Extract Compositions for Forming Protective Coatings

Described herein are methods of preparing cutin-derived monomers, oligomers, or combinations thereof from cutin-containing plant matter. The methods can include heating the cutin-derived plant matter in a solvent at elevated temperature and pressure. In some preferred embodiments, the methods can be carried out without the use of additional acidic or basic species. 3. The method of claim 1 , further comprising adding the cutin to a solvent claim 1 , wherein the decomposing of the cutin is carried out in the solvent.4. The method of claim 3 , wherein the solvent is a nucleophilic solvent.5. The method of claim 3 , wherein the solvent comprises water claim 3 , glycerol claim 3 , methanol claim 3 , ethanol claim 3 , liquid CO claim 3 , supercritical CO claim 3 , or a combination thereof.11. The method of claim 9 , further comprising adding the cutin to a solvent claim 9 , wherein the depolymerizing of the cutin is carried out in the solvent.12. The method of claim 11 , wherein the solvent is a nucleophilic solvent.13. The method of claim 11 , wherein the solvent comprises water claim 11 , glycerol claim 11 , methanol claim 11 , ethanol claim 11 , liquid CO claim 11 , supercritical CO claim 11 , or a combination thereof.14. The method of claim 11 , wherein the decomposing of the compounds of Formula I is also carried out in the solvent.15. The method of claim 9 , further comprising modifying the compounds of Formula II claim 9 , esters thereof claim 9 , or compounds of Formula III to form a second group of compounds of Formula I.19. The method of claim 18 , further comprising adding the cutin to a solvent claim 18 , wherein the decomposing of the cutin is carried out in the solvent.20. The method of claim 19 , wherein the solvent is a nucleophilic solvent.21. The method of claim 19 , wherein the solvent comprises water claim 19 , glycerol claim 19 , methanol claim 19 , ethanol claim 19 , liquid CO claim 19 , supercritical CO claim 19 , or a combination thereof.25. The ...

Raspberry alkoxy esters as a delivery system for natural antioxidants

The present invention relates to raspberry seed oil derivatives derived by the reaction of polyoxyalkylene glycol compounds and cold pressed raspberry seed oil. The choice of pressed raspberry seed oil as a raw material in the preparation of the compounds of the invention is critical, since it has been found that the cold pressed raspberry seed oil contains antioxidants, antimicrobial compounds and which when reacted with a polyoxyalkylene glycol compounds, result in products that deliver said actives to the skin and hair, resulting in protection of the skin and hair from environmental factors such as acid rain, ozone attack and UV degradation.

Synthetic method

A method of alkene metathesis comprising the reaction of at least one monoalkene with ethene in the presence of a diene. The invention also relates to the use of a diene to promote an ethenolysis reaction conducted on a monoalkene. The metathesis catalyst is preferably an alkylidene ruthenium catalyst such as the benzylidene and indenylidene catalysts shown in a). Preferred ethenolysis reactions include those on cashew nut shell liquid comprising the ethenolysis of cardanol to prepare 3-nonen-8-ylphenol and 1-octene. The ethenolysis of methylated anacardic acid (14) to form methyl-2-methoxy-6-(non-8-en-1-yl)benzoate (15) is also disclosed. Hydrogenation of 3-non-8-enylphenol, ethoxylation of the resultant 3-nonylphenol to provide ethoxy-3-nonylphenol or oligoethoxy-3-nonylphenol (as defined herein) is also disclosed.

PROCESS FOR SPLITTING A MIXTURE OF FATTY ACID ESTERS

Intermolecular compound of fatty acid triglyceride

NOVEL COMPOUNDS

An adjuvant suitable for use with a lipophilic agrochemical has the formula (I), R1-(CO)m-O-[-R2O-]n-R 3, wherein R1 is a C16 to C20 straight or branched chain alkyl or alkenyl group, R2 is ethyl or isopropyl, n is from 8 to 30 and m is 0 or 1 and when R2 is ethyl, R 3 is a C1 to C7 alkyl group and when R2 is isopropyl, R3 is hydrogen or a C1 to C7alkyl group, provided that when R1 is oleyl, R2 is isopropyl and R3 is hydrogen, n is not 10. An adjuvant composition comprising an agrochemical and an adjuvant of formula (I) is also claimed. Adjuvants of the invention show effective bioperformance enhancement despite having little or no surfactant properties. © KIPO & WIPO 2007 ...

Synthetic Method

The invention relates to a method of alkene metathesis. In the method, at least one monoalkene is subjected to ethenolysis in the presence of a diene. The invention also relates to the use of a diene to promote an ethenolysis reaction conducted on a monoalkene.

Interesterification catalyst and process

A process for the production of an ester product from a mixture of at least two different ester compounds comprises the steps of mixing together at least two different starting ester compounds to form a first ester mixture; and contacting said first ester mixture with a catalyst comprising from 30 -60% of calcium oxide and at least one second metal oxide at a temperature of at least 180 °C, for a duration of at least one hour, with mixing, to form a second ester mixture having a melting point which is lower than the melting point of said first ester mixture.

Composition and method for treating urea

The present disclosure provides a composition for treating urea particles under ambient atmospheric conditions, a method for treating urea particles with the composition and to a fertiliser treated with the composition. The composition functions to reduce moisture induced agglomeration of treated urea particles compared to moisture induced agglomeration of untreated urea particles. The composition includes a solvent and a mixture of a first and a second aliphatic compound, each compound respectively comprising a selected C ...

PREPARATION OF ESTERIFIED PROPOXYLATED GLYCERIN FROM FREE FATTY ACIDS

PREPARATION OF UNSATURATED MONOESTERS BY THE CATALYTIC OXIDATIVE CARBONYLATION OF DIOLEFINS

A process for the preparation of an unsaturated monoester having the formula RO?CR'=CR'CR'=CHR' wherein R is an alkyl group of from 1 to 8 carbon atoms or an aralkyl group containing 6 carbon atoms in the ring and from 1 to 4 carbon atoms in the alkyl substituent, and R' is hydrogen, a halogen, an alkyl group of from 1 to 4 carbon atoms or an aryl group containing 6 carbon atoms in the ring, by reacting carbon monoxide and oxygen with a diolefin having the formula wherein R' which may be the same or different is as hereinabove described, in the presence of a catalytic amount of a platinum group metal compound, a copper or iron oxidant salt compound and a stoichiometric amount of a dehydrating agent. Alternatively, a ligand or coordination complex compound of the metal salt compound, and catalytic quantities of an alcohol may be employed.

ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF THE SAME FOR DELIVERING NUCLEIC ACID

Provided are an artificially synthesized sphingosine lipoid monomer and the use of same for delivering a nucleic acid. In particular, provided is the use or a method of using a compound of formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a combination comprising the compound of formula I, the stereoisomer thereof or the pharmaceutically acceptable salt thereof to deliver a nucleic acid to a cell or subject, (I) ...

COIX SEED OIL COMPRISING 11 TRIGLYCERIDES, FORMULATION AND APPLICATION THEREOF

A coix seed oil comprising 13 triglycerides extracted from coix seeds, formulation and application thereof. Specifically, the coix seed oil comprises the following 11 triglyceride components (calculated by mass percentage): glyceryl trilinoleate (4.87-6.99%), glyceryl 1-oleate-2,3-dilinoleate (13.00-18.69%), glyceryl 1-palmitate-2,3-dilinoleate (5.25-7.54%), glyceryl1,3-dioleate-2-linoleate (13.23-19.02%), glyceryl 1-palmitate-2-linoleate-3-oleate (10.26-14.75%), glyceryl 1,3-dipalmitate-2-linoleate (2.28-3.28%), glyceryl trioleate (14.44-20.76%), glyceryl 1-palmitate-2,3-dioleate (8.06-11.58%), glyceryl 1-oleate-2-linoleate-3-stearate (1.37-1.97%), glyceryl 1,3-dipalmitate-2-oleate (1.52-2.19%), and 1,2-dioleate-3-stearate (1.29-1.86%). The coix seed oil can be used in the preparation of anti-tumour medicine.

METHOD OF RECOVERING PINOSYLVIN AND OTHER RELATED COMPOUNDS FROM CRUDE TALL OIL

A composition, which is suitable for the production of stilbene compounds, can be separated from tall oil. It con-tains esters of pinosylvin or pinosylvin derivatives and it is concentrated in relation to these. Preferably, the composition contains esters of pinosylvin monomethyl ethers, the acid part of which is formed of an inorganic acid or an organic acid, in particular an organic acid, which is present in the crude tall oil or which is generated from this oil during the process of refining it. Typically, such acids are fatty and resin acids and lower alkane acids. With the invention, it is possible to generate, at an industrial scale, product fractions, and the pinosylvin compounds which are separated from the fractions can be used as such or they can be further modified by means of different chemical methods.

Coix seed oil comprising 11 triglycerides, formulation and application thereof

Process for esterification

POLY-UNSATURATED FATTY ACID ESTER COMPOSITION AND ITS PREPARATION

processo para a reativação de uma resina de troca iônica ácida

PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN

A process for the reactivation of an acidic ion exchange resin is described. The invention relates to the treatment of an at least partially deactivated resin which has been deactivated by contact with an impure ethylenically unsaturated acid or ester containing target impurities. The reactivation includes the step of contacting the at least partially deactivated resin with an alcohol to thereby increase the activity thereof. The invention extends to reactivating a resin deactivated by contact with an impure ethylenically unsaturated acid, ester or nitrile containing target impurities by contacting the at least partially deactivated resin with an alcohol and a carboxylic acid to thereby increase the activity thereof. A reactivated resin and a process for preparing and purifying an ethylenically unsaturated acid or ester of the following formula:- R1-C(=(CH2) m) -COOR2 are also described.

Procédé pour produire des esters carboxyliques d'alcools tertiaires.

NOVEL HIGH VISCOSITY LIQUID BENZOATE ESTER COMPOSITIONS AND POLYMER COMPOSITIONS CONTAINING SAID ESTER COMPOSITIONS

Ester compositions based on blends of the mono- and dibenzoates of 2,2,4-trimethyl-1,3-pentanediol and containing a minimum of 87 weight percent of the dibenzoate are novel and exhibit viscosities that are unexpectedly high relative to the benzoates of other mono-and polyfunctional alcohols. These viscosities are not exhibited at lower concentrations of the dibenzoate.

NOVEL COMPOUNDS

An adjuvant suitable for use with a lipophilic agrochemical has the formula (I), R1-(CO)m-O-[-R2O-]n-R3, wherein R1 is a C16 to C20 straight or branched chain alkyl or alkenyl group, R2 is ethyl or isopropyl, n is from 8 to 30 and m is 0 or 1 and when R2 is ethyl, R3 is a C1 to C7 alkyl group and when R2 is isopropyl, R3 is hydrogen or a C1 to C7 alkyl group, provided that when R1 is oleyl, R2 is isopropyl and R3 is hydrogen, n is not 10. An adjuvant composition comprising an agrochemical and an adjuvant of formula (I) is also claimed. Adjuvants of the invention show effective bioperformance enhancement despite having little or no surfactant properties.

Natural deodorant compositions comprising renewably-based, biodegradable 1,3-propanediol

Disclosed herein are all natural or substantially natural deodorant and antiperspirant compositions comprising 1,3-propanediol wherein the 1,3-propanediol in said all natural or substantially natural deodorant or antiperspirant composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein upon biodegradation, the biologically-derived 1,3-propanediol contributes no anthropogenic CO 2 emissions to the atmosphere.

Compositions comprising mono and di esters of biologically-based 1,3-propanediol

Compositions comprising esters of 1,3-propanediol are provided. The 1,3-propanediol used to form the esters is biologically derived. The esters can have at least 3% biobased carbon. The compositions can further comprise biologically-derived 1,3-propanediol. Also provided are processes for producing compositions comprising esters of 1,3-propanediol. The processes include providing biologically produced 1,3-propanediol, contacting the 1,3-propanediol with an organic acid, which produces an ester, and recovering the produced ester.

2-(2-Benzoxyethoxy)-ethyl-2-furoate

New mixed esters of diols having one hydroxyl group esterified with benzoic acid and the other esterified with various saturated or unsaturated aliphatic acids or aromatic acids other than benzoic are found to have antimicrobial activity against several pathogenic microorganisms, and to have properties making them useful as antimicrobial agents.

Process for the treatment of an ion exchange resin

A process for the reactivation of an acidic ion exchange resin is described. The invention relates to the treatment of an at least partially deactivated resin which has been deactivated by contact with an impure ethylenically unsaturated acid or ester containing target impurities. The reactivation includes the step of contacting the at least partially deactivated resin with an alcohol to thereby increase the activity thereof. The invention extends to reactivating a resin deactivated by contact with an impure ethylenically unsaturated acid, ester or nitrile containing target impurities by contacting the at least partially deactivated resin with an alcohol and a carboxylic acid to thereby increase the activity thereof. A reactivated resin and a process for preparing and purifying an ethylenically unsaturated acid or ester of the following formula:— R 1 —C(═(CH 2 )—COOR 2 are also described.

Lipoxin compounds and their use in treating cell proliferative disorders

Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.

Compositions and methods for using same for treating posterior blepharitis

This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the quality of the meibum lipid composition of inflamed or dysfunctional meibomian glands so as to improve or increase tear break up time, reduce tear osmolarity, and elevate the omega-3 index, while reducing or eliminating the symptoms associated with dry eye or meibomianitis. The dietary or nutritional supplement composition administered to the patient suffering from inflamed or dysfunctional meibomian glands comprises an effective amount of omega-3 fatty acids. 1. A method for treating posterior blepharitis comprising administering a dietary or nutritional supplement comprising an effective amount of omega-3 fatty acids , wherein said effective amount includes between 600 mg and 5 ,000 mg on a daily dosage basis.2. The method for treating posterior blepharitis as defined in claim 1 , wherein said effective amount includes between 2 claim 1 ,000 mg and 3 claim 1 ,000 mg on a daily dosage basis.3. The method for treating posterior blepharitis as defined in claim 1 , wherein said omega-3 fatty acids comprise the triglyceride form.4. The method for treating posterior blepharitis as defined in claim 1 , wherein said omega-3 fatty acids include an effective amount of eicosapentaenoic acid (EPA).5. The method for treating posterior blepharitis as defined in claim 4 , wherein said EPA comprises the triglyceride form.6. The method for treating posterior blepharitis as defined in claim 4 , wherein said effective amount of EPA comprises an amount greater than 600 mg.7. The method for treating posterior blepharitis as defined in claim 4 , wherein said effective amount of EPA comprises an amount between 1 claim 4 ,600 mg and 2 claim 4 ,500 mg.8. The method for treating posterior blepharitis as defined in claim 4 , wherein said EPA comprises an amount between 1 claim 4 ,600 mg and 1 claim 4 ,800 mg.9. The method for treating ...

Dielectric Fluids Comprising Polyol Esters

Dielectric fluids are provided, the dielectric fluids comprising a mixture of polyol esters derived from a reaction of a) a polyol comprising pentaerythritol, trimethylolpropane, neopentyl glycol, or combinations thereof, and b) a mixture of fatty acid esters derived from a high oleic soybean oil comprising fatty acid moieties, wherein the high oleic soybean oil has a C18:1 content of greater than 65% of the fatty acid moieties in the oil, and a combined C18:2 and C18:3 content of less than 20% of the fatty acid moieties in the oil. Also provided are electrical apparatuses comprising the dielectric fluids, and processes for preparing the mixtures of polyol esters.

PROCESS FOR THE DISTILLATION OF FATTY ACID ESTERS

The present invention relates to a method for working up a mixture which contains esters of EPA and/or DHA with monohydric alcohols having 1 to 6 carbon atoms, esters of other fatty acids with monohydric alcohols having 1 to 6 carbon atoms, and free cholesterol, wherein the method comprises adding a transesterification catalyst to the mixture, converting at least some of the free cholesterol into esterified cholesterol and thereafter distilling the mixture, wherein the distillation is carried out in such a manner that a product is obtained which contains EPA and/or DHA, both in the form of esters thereof with monohydric alcohols having 1 to 6 carbon atoms, in a higher relative amount, based on all fatty acids in free or bound form present in the product, than said mixture. In addition, the present invention relates to a product which is obtainable by the method according to the invention, wherein the product contains 10 to 99.99% by weight of esters of EPA and/or of DHA with monohydric alcohols having 1 to 6 carbon atoms and 0.0001 to a maximum of 0.3% by weight of cholesterol in free or bound form. 19-. (canceled)11. The method according to claim 10 , wherein the transesterification catalyst is selected from the group consisting of a lipase claim 10 , an alkali metal salt of a monohydric alcohol having 1 to 6 carbon atoms and sodium ethanolate.12. The method according to claim 10 , wherein the mixture is obtained from a fish oil by transesterification with a monohydric alcohol having 1 to 6 carbon atoms.13. The method according to claim 12 , wherein the monohydric alcohol is ethanol.14. The method according to claim 10 , wherein the mixture comprises10 to 40% by weight esters of EPA and/or DHA with monohydric alcohols having 1 to 6 carbon atoms,50 to 90% by weight esters of other fatty acids with monohydric alcohols having 1 to 6 carbon atoms and0.1 to 1% by weight free cholesterol.15. The method according to claim 10 , wherein a washing step with water and ...

Deuterated compounds, compositions, and methods of use

Deuterated polyunsaturated fatty acid (“PUFA”) compounds, compositions, and uses of the compounds for reducing lipid autooxidation and the treatment of various diseases and conditions are provided.

COMPOUNDS WITH A COMBINED ANTIOXIDANT ACTIVITY AGAINST FREE RADICALS TOGETHER WITH AN ANTI-INFLAMMATORY ACTION, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF SKIN AND HAIR

The invention relates to 2,4,6-octatrienoic acid derivative compounds having general formula (I) (CH—CH═CH—CH═CH—CH═CH—CO—O—)—R (I) consisting of esters wherein n=1, 2, 3 and wherein R is selected from alkyl, aryl or cycloalkyl of a polyol, phenol or phenolic acid; or consisting of a salt wherein n=1 and R=arginine, as active ingredients in a pharmaceutical or cosmetic composition having a combined antioxidant activity against free radicals together with an anti-inflammatory action. 115.-. (canceled)17. Compounds according to claim 16 , characterized in that said polyol claim 16 , phenol or phenolic acid is selected from glycerol claim 16 , sitosterol claim 16 , resveratrol claim 16 , caffeic acid claim 16 , ferulic acid claim 16 , gallic acid.18. Compounds according to claim 16 , characterized in that they are selected from the following: caffeic acid 3 claim 16 ,4-di-octatrienoate claim 16 , sitosterol octatrienoate claim 16 , resveratrol octatrienoate claim 16 , resveratrol di-octatrienoate claim 16 , resveratrol tri-octatrienoate claim 16 , glycerol tri-octatrienoate claim 16 , octatrienoic acid arginine salt claim 16 , ferulic acid octatrienoate claim 16 , octatrienoic ferulic 4-(2 claim 16 ,4 claim 16 ,6-octatrienoyl)anhydride claim 16 , gallic acid tri-octatrienoate.19. A composition for topical application to the human skin or scalp for obtaining a combined antioxidant activity against free radicals together with an anti-inflammatory action claim 16 , wherein the active ingredient is a compound of general formula (I){'br': None, 'sub': 3', 'n—R, '(CH—CH═CH—CH═CH—CH═CH—CO—O—)\u2003\u2003(I)'}consisting of esters, wherein n=1, 2, 3 and wherein R is selected from alkyl, aryl or cycloalkyl of a polyol, phenol or phenolic acid; or consisting of a salt wherein n=1 and R=arginine.20. The composition according to claim 19 , wherein a compound of general formula (I) is used as the active ingredient formulated with excipients for topical application to the skin for ...

COMPOSITION CONTAINING EICOSAPENTAENOIC ACID ALKYL ESTER, AND METHOD FOR PRODUCING SAME

Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography. 1. An eicosapentaenoic acid alkyl ester-containing composition which , upon measurement by gas chromatography , comprises 96 to 99 area % of an eicosapentaenoic acid alkyl ester , wherein the composition satisfies at least one of the following (i)-(iii):(i) the content of a n-nonadecanoic acid (C19:0) alkyl ester is 0.1 area % or less,(ii) the content of an arachidic acid (C20:0) alkyl ester is 0.2 area % or less, and(iii) the content of an icosa-5,9,11,14,17-pentaenoic acid (C20:5 n-3(5,9,11,14,17)) alkyl ester is 0.2 area % or less.2. The composition of claim 1 , wherein the content of mono-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less.3. The composition of claim 1 , wherein the sum of the contents of mono-trans forms and di-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less.4. The composition of claim 1 , wherein the sum of the contents of mono-trans forms claim 1 , di-trans forms and tri-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less.5. The composition of claim 1 , wherein the sum of the contents of mono-trans forms claim 1 , di-trans forms claim 1 , tri-trans forms and tetra-trans forms of the eicosapentaenoic acid ...

Conjugated Diene Acids and Derivatives Thereof

Conjugated diene acids and derivatives thereof, are disclosed herein. In some embodiments, the conjugated diene acids and derivatives thereof are derived from the metathesis of a natural oil followed by isomerization. Uses of conjugated diene acids and derivatives thereof in various compositions are also disclosed herein.

MULTI-STEP SEPARATION PROCESS

The present invention provides a chromatographic separation process for recovering a polyunsaturated fatty acid (PUFA) product from a feed mixture, which comprises: (a) purifying the feed mixture in a first chromatographic separation step using an eluent a mixture of water and a first organic solvent, to obtain an intermediate product; and (b) purifying the intermediate product in a second chromatographic separation step using as eluent a mixture of water and a second organic solvent, to obtain the PUFA product, wherein the second organic solvent is different from the first organic solvent and has a polarity index which differs from the polarity index of the first organic solvent by between 0.1 and 2.0, wherein the PUFA product is other than alpha-linolenic acid (ALA), gamma-linolenic acid (GLA), linoleic acid, an ALA mono- di- or triglyceride, a GLA mono- di- or triglyceride, a linoleic acid mono- di- or triglyceride, an ALA C-Calkyl ester, a GLA C-Calkyl ester or a linoleic acid C-Calkyl ester or a mixture thereof. 2. The process according to claim 1 , wherein the first chromatographic separation step consists of two chromatographic separations claim 1 , wherein each separation uses as eluent a mixture of water and the first organic solvent.3. The process according to claim 1 , wherein the second chromatographic separation step consists of two chromatographic separations claim 1 , wherein each separation uses as eluent a mixture of water and the second organic solvent.4. The process according to claim 1 , wherein the first and second organic solvents are chosen from alcohols claim 1 , ethers claim 1 , esters claim 1 , ketones and nitriles.5. The process according to claim 4 , wherein the ketone is acetone claim 4 , methylethylketone or methyl isobutyl ketone (MIBK) claim 4 , preferably acetone.6. The process according to claim 1 , wherein one of the first and second organic solvents is methanol.7. The process according to claim 1 , wherein the second organic ...

COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION

The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications. 2. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.3. The pharmaceutical composition of claim 2 , wherein said pharmaceutical composition is formulated to treat for oral administration claim 2 , delayed release or sustained release claim 2 , transmucosal administration claim 2 , syrup claim 2 , topical administration claim 2 , parenteral administration claim 2 , injection claim 2 , subdermal ration claim 2 , oral solution claim 2 , rectal administration claim 2 , buccal administration or transdermal administration.4. The pharmaceutical composition of claim 3 , wherein said pharmaceutical composition is formulated for the treatment of inflammation claim 3 , inflammatory pain and post-surgery inflammation.5. (canceled) The present application is a continuation U.S. patent application Ser. No. 16/446,604, filed on Jun. 19, 2019, which is a continuation of International Patent Application No. PCT/IB2017/052246, filed Apr. 19, 2017, which claims the benefit of Indian Provisional Patent Application No. 201641043342 filed on Dec. 19, 2016, and the contents of each application are incorporated in their entirety herein by reference.This disclosure generally relates to compounds and compositions for the treatment of inflammation. More particularly, this invention relates to treating subjects with a pharmaceutically acceptable dose of compounds, crystals, solvates, enantiomer, stereoisomer, esters, salts, hydrates, ...

FREE-POLYUNSATURATED-FATTY-ACID-CONTAINING COMPOSITION AND METHOD FOR MANUFACTURING SAME

Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is at least 80.0% of the amount of fatty acids in the composition; and a method for manufacturing a free-polyunsaturated-fatty-acid-containing composition, comprising: providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms; performing a hydrolysis treatment on a reaction solution prepared by combining the provided raw material composition, a lower alcohol, water having a total metal content of 0.01 ppm or less, and an alkali catalyst; and limiting the contact between the reaction composition and the metal after the hydrolysis treatment so that the product T [cm×days] of the contact surface area [cm] per 1 g and the contact time [days] between the composition and the metal is 100 or less. 18-. (canceled)9. A manufacturing method of a free polyunsaturated fatty acid-containing composition , the method comprising:providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbons;performing hydrolysis treatment on a reaction solution prepared by combining the provided raw material composition, a lower alcohol, water having a total content of metal of 0.01 ppm or less, and an alkali catalyst; and{'sup': 2', '2, 'limiting contact between the reaction composition after the hydrolysis treatment and a metal surface such that a product T (cm×day) of a contact surface area (cm) per 1 g of the composition with the metal surface and contact time (day) becomes 100 or less.'}10. The manufacturing method according to claim 9 , wherein the product T (cm×day) of the contact surface area (cm) per 1 g of the composition with the metal surface and the contact time (day) becomes 80 or less.11. The manufacturing method according to claim 9 , wherein a ...

COMPOSITION CONTAINING EICOSAPENTAENOIC ACID ALKYL ESTER, AND METHOD FOR PRODUCING SAME

Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography. 2. The composition of claim 1 , wherein the content of an arachidonic acid alkyl ester is 0.7 area % or less.3. The composition of claim 1 , wherein the content of the arachidonic acid alkyl ester is 0.1 area % or less.4. The composition of claim 1 , wherein the content of an eicosatetraenoic acid alkyl ester is 0.7 area % or less.5. The composition of claim 1 , wherein the content of an octadecatetraenoic acid alkyl ester is 0.4 area % or less.6. The composition of claim 1 , wherein the content of a nonadecapentaenoic acid alkyl ester is 0.2 area % or less.7. The composition of claim 1 , wherein the eicosapentaenoic acid alkyl ester is ethyl eicosapentaenoate or methyl eicosapentaenoate.8. The composition of claim 1 , wherein the content of a n-nonadecanoic acid (C19:0) alkyl ester is 0.1 area % or less.9. The composition of claim 1 , wherein the content of an arachidic acid (C20:0) alkyl ester is 0.2 area % or less.10. The composition of claim 1 , wherein the content of alkyl esters of saturated fatty acids is 0.5 area % or less.11. The composition of claim 1 , wherein the content of an icosa-5 claim 1 ,9 claim 1 ,11 claim 1 ,14 claim 1 ,17-pentaenoic acid (C20:5n-3(5 claim 1 ,9 claim 1 ,11 claim ...

NEW LIPOPHENOL COMPOUNDS AND USES THEREOF

The present invention relates to a compound of formula (I) wherein: —i is 0 or 1; j is 0 or 1; k is 0 or 1; —Rand Rare in particular H, (C-C)alkyl, or a group of formula C(O)R; —R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; —Ris H and k=0 when j=1; or, when j=0, Ris —C(O)R or -L-C(O)R; —L, U and L″ are linkers; wherein, when j=0, at least one of the groups R; Rand Rcomprises a radical R. 2. The compound of claim 1 , wherein claim 1 , when j=0 claim 1 , at most one of the groups R claim 1 , Rand Ris H.5. The compound of claim 4 , wherein Ris an alkyl group.10. The compound of claim 1 , wherein Ris a (C-C)alkyl group claim 1 , preferably a (C-C)alkyl group claim 1 , and more preferably an isopropyl group.11. The compound of claim 1 , wherein R is a linear or branched alkyl group claim 1 , possibly interrupted by one or several double bonds claim 1 , comprising from 19 to 23 carbon atoms.12. The compound of claim 1 , wherein R is a linear or branched alkyl group claim 1 , possibly interrupted by one or several double bonds claim 1 , comprising from 19 to 23 carbon atoms claim 1 , and wherein one or several hydrogen atoms are replaced by deuterium atoms.13. The compound of claim 1 , wherein R is a linear or branched alkyl group claim 1 , interrupted by at least one double bond claim 1 , comprising from 19 to 21 carbon atoms.16. A pharmaceutical composition comprising the compound according to claim 1 , in association with a pharmaceutically acceptable vehicle.17. A method for treating a pathology involving both carbonyl and oxidative stress claim 1 , comprising a step of administering a pharmaceutically acceptable amount of the compound of to a patient in need thereof.18. The compound of claim 17 , wherein the pathology involving carbonyl and oxidative stress is chosen from the group consisting of: inflammatory and infectious diseases claim 17 , cardiovascular diseases claim 17 , metabolic diseases claim 17 , cancer claim 17 , retinal ...

Inhibitor Combination for Lithium Salt-Catalyzed Transesterification Process and Method for Removing Lithium Salt

A process to form a composition comprising an asymmetrical polyene, the asymmetrical polyene comprising an “α,β unsaturated-carbonyl end” and a “C—C double bond end,” the process comprising: reacting an alkene- or polyene-containing alcohol with an alkyl ester of an α,β unsaturated carboxylic acid in the presence of at least the following components A) through C) to form a solution comprising an asymmetrical polyene: 2. The composition of comprising from 25 ppm to less than 100 ppm claim 1 , based on the weight of the composition claim 1 , of the inhibitor selected from the group consisting of 4-HT and derivatives thereof.3. The composition of comprising from 50 ppm to less than 2000 ppm claim 1 , based on the weight of the composition claim 1 , of MeHQ.4. The composition of further comprising less than 10 wt % unreacted alkene- or polyene-containing alcohol claim 1 , based on the total weight of the composition.5. The composition of comprising from 2 wt % to less than 10 wt % unreacted alkene- or polyene-containing alcohol claim 4 , based on the total weight of the composition claim 4 , wherein the unreacted alkene- or polyene-containing alcohol is polypropylene glycol allyl ether.6. The composition of further comprising less than 10 wt % of Michael adducts claim 1 , based on the total weight of the composition.7. The composition of further comprising a lithium salt.8. The composition of claim 7 , wherein the lithium salt has the structure LiX claim 7 , wherein n is 1 or 2; and X is selected from the group consisting of hydroxide claim 7 , oxide claim 7 , halide claim 7 , carbonate claim 7 , bicarbonate claim 7 , alkoxide claim 7 , alkonate claim 7 , alkenoate claim 7 , phenoxide claim 7 , sulfate claim 7 , bisulfate claim 7 , sulfonate claim 7 , phosphate claim 7 , phosphonate claim 7 , perchlorate claim 7 , and nitrate.9. The composition of claim 7 , wherein the lithium salt has the structure LiX claim 7 , wherein n is 1 or 2; and X is selected from the group ...

PRODUCTION AND PURIFICATION OF ESTERS OF POLYUNSATURATED FATTY ACIDS

The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation. 1. A method for purifying a composition comprising triglycerides having polyunsaturated fatty acid residues comprising:a) reacting the composition in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides; andb) distilling the composition to recover a fraction comprising the ester of the polyunsaturated fatty acid.2. The method of claim 1 , wherein the step of reacting the composition in the presence of an alcohol and a base is performed at a temperature from about 60° C. to about 120° C.3. The method of claim 1 , wherein the step of reacting the composition in the presence of an alcohol and a base is performed for a time from about 2 hours to about 12 hours.4. The method of claim 1 , wherein the composition comprising triglycerides having polyunsaturated fatty acid residues has not been subjected to one or more treatments selected from the group consisting of refining claim 1 , desolventization claim 1 , deodorization claim 1 , winterization claim 1 , chill filtration claim 1 , and bleaching.5. The method of claim 1 , wherein the composition comprising triglycerides having polyunsaturated fatty acid residues has not been subjected to refining claim 1 , desolventization claim 1 , deodorization claim 1 , winterization claim 1 , chill filtration claim 1 , and bleaching.6. The method of claim 1 , wherein the composition comprising triglycerides having polyunsaturated fatty acid residues is from a source selected from ...

(E)-2-ISOPROPYL-5-METHYL-3,5-HEXADIENOATE COMPOUND, METHOD FOR PRODUCING THE SAME, AND METHODS FOR PRODUCING (E)-2-ISOPROPYL-5-METHYL-3,5-HEXADIENOL AND (E)-2-ISOPROPYL-5-METHYL-3,5-HEXADIENYL CARBOXYLATE BY USING THE SAME

Provided is a geometrically selective method for producing (±)-(E)-2-isopropyl-5-methyl-3,5-hexadienyl acetate, which is a sex pheromone of grape pineapple mealybug (GPMB). Specifically provided is a method for producing a an (E)-2-isopropyl-5-methyl-3,5-hexadienyl carboxylate compound (4), the method comprising the steps of: dehydrating a 3-hydroxy-2-isopropyl-5-methyl-4-hexenoate compound (1) to obtain an (E)-2-isopropyl-5-methyl-3,5-hexadienoate compound (2); reducing the alkoxycarbonyl group of the compound (2) to obtain (E)-2-isopropyl-5-methyl-3,5-hexadienol (3); and esterifying the compound (3) to obtain the compound (4). This application claims priority from Japanese Patent Application No. 2015-161019, filed Aug. 18, 2015, the disclosure of which is incorporated by reference herein in its entirety.The present invention relates to an (E)-2-isopropyl-5-methyl-3,5-hexadienoate compound useful as a synthetic perfume or as a synthetic intermediate in organic synthesis; a method for producing the hexadienoate compound; and a method for producing (E)-2-isopropyl-5-methyl-3,5-hexadienol. The present invention also relates to a method for producing an (E)-2-isopropyl-5-methyl-3,5-hexadienyl carboxylate useful as a bioactive substance such as an insect sex pheromone and a substance related therewith. For example, the present invention relates to a method for producing (E)-2-isopropyl-5-methyl-3,5-hexadienyl acetate, which is a sex pheromone of (generic name: grape pineapple mealybug).The sex pheromones of insects are biologically active substances that are commonly secreted by female individuals and have the function of attracting male individuals. A small amount of a sex pheromone shows a strong attraction activity. The sex pheromones have been widely used as means for forecasting insect emergence or for ascertaining regional spread (i.e. invasion into a specific area) of the insect pests and as means for controlling insect pests. As the means for controlling insect ...

Method of Manufacturing Bio-Diesel and Reactor

A reactor and process for the production of bio-diesel. The reactor includes one or more coiled reaction lines. The lines are positioned within a tank containing a heat transfer media such as molten salt, maintained at about 750° F. A pump circulates the media within the tank. An emulsion of alcohol; refined feed stock, including glycerides and/or fatty acids; and preferably water is pumped through the reaction lines at temperatures and pressures sufficient to maintain the alcohol in a super-critical state. The curvature of the coils, pump pulsing, and the flow rate of the emulsion keep the emulsion in a turbulent state while in the reactor, ensuring thorough mixing of the alcohol and feed stock. The alcohol reacts with the glycerides and fatty acids to form bio-diesel. The reaction is fast, efficient with regard to energy input and waste generation, and requires minimal alcohol.

ADHESION PREVENTING AGENT

The present invention relates to an adhesion preventing agent comprising an amphipathic compound having the following general formula (I): 2. The adhesion preventing agent according to claim 1 , wherein n denotes the integer 1 or 2 in the formula.3. The adhesion preventing agent according to claim 1 , wherein R in the formula denotes a hydrophilic group generated by removal of one hydroxyl group from any one selected from the group consisting of glycerol claim 1 , erythritol claim 1 , pentaerythritol claim 1 , diglycerol claim 1 , glyceric acid claim 1 , triglycerol claim 1 , xylose claim 1 , sorbitol claim 1 , ascorbic acid claim 1 , glucose claim 1 , galactose claim 1 , mannose claim 1 , dipentaerythritol claim 1 , maltose claim 1 , mannitol claim 1 , and xylitol.4. The adhesion preventing agent according to claim 1 , wherein R in the formula denotes a hydrophilic group generated by removal of one hydroxyl group from glycerol claim 1 , erythritol claim 1 , diglycerol claim 1 , or xylose.5. The adhesion preventing agent according to claim 1 , wherein the amphipathic compound is any one of the following compounds:mono-O-(5,9,13-trimethyltetradec-4-enoyl)glycerol,mono-O-(5,9,13,17-tetramethyloctadec-4-enoyl)diglycerol,mono-O-(5,9,13-trimethyltetradecanoyl)glycerol,mono-O-(5,9,13,17-tetramethyloctadecanoyl)erythritol,1-O-(3,7,11,15-tetramethylhexadecyl)-β-D-xylopyranoside, andmono-O-(5,9,13-trimethyltetradec-4,8,12-trienoyl)glycerol.6. The adhesion preventing agent according to claim 1 , further comprising a pharmaceutically acceptable carrier.7. The adhesion preventing agent according to claim 6 , wherein the carrier is a liquid carrier and/or a gas carrier.8. The adhesion preventing agent according to claim 7 , wherein the liquid carrier comprises at least one selected from the group consisting of silicone oil claim 7 , alcohol claim 7 , and an aqueous medium.9. The adhesion preventing agent according to claim 1 , further comprising a pharmaceutically acceptable ...

HIGHLY UNSATURATED FATTY ACID OR HIGHLY UNSATURATED FATTY ACID ETHYL ESTER WITH REDUCED ENVIRONMENTAL POLLUTANTS, AND METHOD FOR PRODUCING SAME

A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester that has been produced using as a feedstock oil a fat or oil that contains highly unsaturated fatty acids as constituent fatty acids and which has been reduced in the contents of environmental pollutants, wherein among the dioxins contained, polychlorinated dibenzoparadioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) are contained in amounts of less than 0.05 pg-TEQ/g and coplanar PCBs (Co-PCBs) in amounts of less than 0.03 pg-TEQ/g. Also disclosed is a method for producing the highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester by the steps of removing free fatty acids and environmental pollutants by thin-film distillation from a feedstock oil, ethyl esterifying the resulting fat or oil, and refining the same by rectification and column chromatography. 1. A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester which has been produced using as a feedstock oil or fat derived from marine products that contains highly unsaturated fatty acids as constituent fatty acids ,wherein the highly unsaturated fatty acid or the highly unsaturated fatty acid ethyl ester contains an amount of coplanar PCBs (Co-PCBs) up to 0.03 pg-TEQ/g, andwherein the highly unsaturated fatty acid comprises eicosapentaenoic acid, dihomo-γ-linoleic acid, docosahexaenoic acid, docosapentaenoic acid, or a combination thereof;wherein a concentration as occupied by the highly unsaturated fatty acids in the sum of fatty acids is at least 80 area %.2. The highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester according to claim 1 , wherein an amount of a brominated flame retardant contained in the unsaturated fatty acid or the unsaturated fatty acid ester has been reduced to such a level that the amount of BDE-47 is less than 0.18 ng/g claim 1 , the amount of BDE-100 is less than 0.03 ng/g claim 1 , the amount of BDE-49 is less than 0.05 ng/g claim 1 , or ...

MONOMERS AND POLYMERS FORMED THEREBY

Monomers, polymers, or oligomers formed therefrom and methods of forming or utilizing monomers of formula I 2. The polymer according to claim 1 , wherein Ris a methyl group claim 1 , an ethyl group claim 1 , a propyl group claim 1 , an n-butyl group claim 1 , or a t-butyl group.3. The polymer according to claim 1 , wherein X is —OR.4. The polymer according to claim 3 , wherein Ris a Cto Calkyl.5. The polymer according to claim 3 , wherein Ris 2-ethylhexyl.6. The polymer according to claim 3 , wherein Ris a hydrocarbon moiety of bio-renewable alcohol or a hydrogenated derivative thereof.7. The polymer according to claim 1 , wherein X is OM.8. The polymer according to claim 1 , wherein the monomer according to formula I is polymerized with a secondary monomer not of formula I.9. The polymer according to claim 1 , wherein the precursor monomer is co-polymerized with the acid of the precursor monomer.10. The polymer according to claim 1 , wherein the polymer is crosslinked.11. The polymer according to claim 1 , wherein the polymer is a hydrogel and can hold at least about 100 times its weight in water.12. The polymer according to claim 8 , wherein the secondary monomer is selected from isoprene claim 8 , butadiene claim 8 , styrene claim 8 , sorbic acid (or its alkali metal salts) claim 8 , a sorbate ester claim 8 , (meth)acrylic acid (or its alkali metal salts) claim 8 , (meth)acrylate ester claim 8 , or combinations thereof.14. The method according to further comprising precipitating or crystallizing the mixture to form a solid substance.15. The method according to further comprising polymerizing the mixture and crosslinking the polymer.17. The monomer of claim 17 , wherein the monomer is of formula III and Y is a linker group commonly used in a bis-acrylate or bis-methacrylate crosslinking agent typically utilized in acrylate or methacrylate polymerization reactions.18. The monomer of claim 17 , wherein the monomer is of formula III and Y is —(CHCHO)—CHCH claim 17 , ...

Free polyunsaturated fatty acid-containing composition and manufacturing method therefor

The present disclosure is: a free polyunsaturated fatty acid-containing composition, which comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, the content being at least 80.0% of the fatty acids in the composition, and satisfies at least one selected from a group consisting of conditions (1) and (2): (1) the content of conjugated unsaturated fatty acid is 1.0% or less of the fatty acids in the composition, and (2) the Gardner color is less than 3+; and a manufacturing method for the free polyunsaturated fatty acid-containing composition comprising the preparation of a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms, and hydrolysis of a reaction solution containing the prepared raw material composition, a lower alcohol, water and an alkali catalyst at a temperature of 10° C. or lower.

LIPID COMPRISING LONG CHAIN POLYUNSATURATED FATTY ACIDS

The present invention relates to extracted plant lipid or microbial lipid comprising docosahexaenoic acid, and/or docosapentaenoic acid, and processes for producing the extracted lipid. 1. Extracted plant lipid , comprising fatty acids in an esterified form , the fatty acids comprising oleic acid , palmitic acid , ω6 fatty acids which comprise linoleic acid (LA) , ω3 fatty acids which comprise α-linolenic acid (ALA) and docosahexaenoic acid (DHA) , and optionally one or more of stearidonic acid (SDA) , eicosapentaenoic acid (EPA) , docosapentaenoic acid (DPA) and eicosatetraenoic acid (ETA) , wherein the level of palmitic acid in the total fatty acid content of the extracted lipid is between about 2% and 16% , and wherein the level of myristic acid (C14:0) in the total fatty acid content of the extracted lipid , if present , is less than 1% , and wherein the level of DHA in the total fatty acid content of the extracted lipid is between 20.1% and 35%.2. The extracted plant lipid of which has one or more of the following featuresi) the level of palmitic acid in the total fatty acid content of the extracted plant lipid is between about 2% and 15%, or between about 3% and about 10%,ii) the level of myristic acid (C14:0) in the total fatty acid content of the extracted plant lipid is about 0.1%,iii) the level of oleic acid in the total fatty acid content of the extracted plant lipid is between about 1% and about 30%, between about 3% and about 30%, between about 6% and about 30%, between 1% and about 20%, between about 30% and about 60%, about 45% to about 60%, about 30%, or between about 15% and about 30%,iv) the level of linoleic acid (LA) in the total fatty acid content of the extracted plant lipid is between about 4% and about 35%, between about 4% and about 20%, between about 4% and about 17%, or between about 5% and about 10%,v) the level of α-linolenic acid (ALA) in the total fatty acid content of the extracted plant lipid is between about 4% and about 40%, ...

Use of sarmentine and its analogs for controlling plant pests

Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.

Polyol Esters of Metathesized Fatty Acids and Uses Thereof

Polyol esters of metathesized fatty acids are generally disclosed herein. Methods of using such compounds, for example, as cleaning agents, solvents, and coalescents for paints and coatings, are also disclosed. 162-. (canceled)64. The compound of claim 63 , wherein Ris —H.65. The compound of claim 63 , wherein Ris —CH—CH claim 63 , —CH—CH═CH claim 63 , or —CH—CH═CH—CH—CH.66. The compound of claim 65 , wherein Ris —CH—CH.67. The compound of claim 65 , wherein Ris —CH—CH═CH.68. The compound of claim 65 , wherein Ris —CH—CH═CH—CH—CH.69. The compound of claim 63 , wherein R is —CH—CH(—O—CH—CH)—OH.70. The compound of claim 69 , wherein w is 1 or 2.71. The compound of claim 63 , wherein R is —CH—CH(—O—CH—CH)—O—R.72. The compound of claim 71 , wherein Ris methyl.73. The compound of claim 71 , wherein Ris ethyl.74. The compound of claim 71 , wherein x is 1 or 2.75. The compound of claim 63 , wherein R is —CH—CH(—CH)(—O—CH—CH(—CH))—OH.76. The compound of claim 75 , wherein y is 1 or 2.77. The compound of claim 63 , wherein R is —CH—CH(—CH)(—O—CH—CH(—CH))—O—R.78. The compound of claim 77 , wherein Ris methyl.79. The compound of claim 77 , wherein Ris ethyl.80. The compound of claim 77 , wherein z is 1 or 2.8193-. (canceled)94. A paint or coating composition claim 77 , comprising:a film-forming polymer;water; and{'claim-ref': {'@idref': 'CLM-00063', 'claim 63'}, 'a compound of .'}95103-. (canceled)104. The composition of claim 94 , wherein the composition has no more than 0.5 kg/L of volatile organic compounds (VOCs) claim 94 , as measured by Method 24 of the United States Environmental Protection Agency.105108-. (canceled) The present application is a continuation of U.S. patent application Ser. No. 15/075,734, filed Mar. 21, 2016, which claims the benefit of priority of United States Provisional Application Nos. 62/137,685, filed Mar. 24, 2015, and 62/236,034, filed Oct. 1, 2015, each of which is hereby incorporated by reference in its entirety.Polyol esters of metathesized ...

COLORED OXYGEN SCAVENGING COMPOSITIONS REQUIRING NO INDUCTION PERIOD

The present invention provides a composition comprising: a polyester base polymer; an oxidizable polyether-based additive; a transition metal catalyst; a colorant; and a polyunsaturated fatty ester additives, wherein the polyester base polymer is substantially free of antimony and substantially free of phosphorous. Containers made from the composition are colored and exhibit excellent oxygen scavenging properties with no induction period. 1. A composition comprising:a polyester base polymer that is substantially free of antimony and substantially free of phosphorous;an oxidizable polyether-based additive;a transition metal catalyst;a colorant; and{'sub': x', 'y, 'claim-text': R is an alkyl, a alkylene, a trivalent alkane group, or a glyceryl moiety;', 'n ranges from 1 to 3;', 'x ranges from 16 to 20; and', 'y ranges from 27 to 35., 'a polyunsaturated fatty ester oil with the formula R—[OCOCH], wherein,'}2. The composition of claim 1 , wherein the polyester base polymer contains less than 100 ppm each of antimony and phosphorous.3. The composition of claim 1 , wherein the polyester base polymer contains less than 10 ppm each of antimony and phosphorous.4. The composition of claim 1 , wherein the polyester base polymer comprises polyethylene terephthalate.5. The composition of claim 1 , wherein the oxidizable polyether-based additive has the formula X—[R—O]—R′—Y claim 1 , whereinR is a substituted or unsubstituted alkylene chain having from 2 to 10 carbon atoms;n ranges from 4 to 100;{'sub': 1', '1', '1', '1', '1', '1, 'X and Y are selected from the group consisting of H, OH, —OCOR, —OCOAr, —OR, and —OAr, wherein Ris an alkyl group having from 2 to 18 carbon atoms and Aris an aryl group; and'} {'sub': 2', '3', 'p', '2', '3', 'p', '2', '2', '3', '2', '18, '—[CORCOORO]— and —[COArCOORO]— wherein Aris a phenylene or naphthylene group, Rand Rare Cto Calkylene groups, and p ranges from 10 to 100.'}, 'R′ may be the same as R or selected from the group consisting of'}6. The ...

HIGHLY UNSATURATED FATTY ACID OR HIGHLY UNSATURATED FATTY ACID ETHYL ESTER WITH REDUCED ENVIRONMENTAL POLLUTANTS, AND METHOD FOR PRODUCING SAME

A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester that has been produced using as a feedstock oil a fat or oil that contains highly unsaturated fatty acids as constituent fatty acids and which has been reduced in the contents of environmental pollutants, wherein among the dioxins contained, polychlorinated dibenzoparadioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) are contained in amounts of less than 0.05 pg-TEQ/g and coplanar PCBs (Co-PCBs) in amounts of less than 0.03 pg-TEQ/g. Also disclosed is a method for producing the highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester by the steps of removing free fatty acids and environmental pollutants by thin-film distillation from a feedstock oil, ethyl esterifying the resulting fat or oil, and refining the same by rectification and column chromatography. 1. A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester which has been produced using as a feedstock oil a fat or oil that contains highly unsaturated fatty acids as constituent fatty acids and which has been reduced in the contents of environmental pollutants , wherein among the dioxins contained , polychlorinated dibenzoparadioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) are contained in amounts of less than 0.05 pg-TEQ/g and coplanar PCBs (Co-PCBs) in amounts of less than 0.03 pg-TEQ/g.2. The highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester according to claim 1 , wherein the content of a brominated flame retardant contained has been reduced to such a level that the amount of BDE-47 is less than 0.18 ng/g claim 1 , the amount of BDE-100 is less than 0.03 ng/g claim 1 , the amount of BDE-49 is less than 0.05 ng/g claim 1 , or the amount of BDE-99 is less than 0.05 ng/g.3. The highly unsaturated fatty acid ethyl ester according to claim 1 , wherein the concentration as occupied by highly unsaturated fatty acids in the sum of fatty acids is at least ...

MULTI-STEP SEPERATION PROCESS

The present invention provides a chromatographic separation process for recovering a polyunsaturated fatty acid (PUFA) product from a feed mixture, which comprises: (a) purifying the feed mixture in a first chromatographic separation step using an eluent a mixture of water and a first organic solvent, to obtain an intermediate product; and (b) purifying the intermediate product in a second chromatographic separation step using as eluent a mixture of water and a second organic solvent, to obtain the PUFA product, wherein the second organic solvent is different from the first organic solvent and has a polarity index which differs from the polarity index of the first organic solvent by between 0.1 and 2.0, wherein the PUFA product is other than alpha-linolenic acid (ALA), gamma-linolenic acid (GLA), linoleic acid, an ALA mono- di- or triglyceride, a GLA mono- di- or triglyceride, a linoleic acid mono- di- or triglyceride, an ALA C-Calkyl ester, a GLA C-Calkyl ester or a linoleic acid C-Calkyl ester or a mixture thereof. 1. A composition comprising a PUFA product , wherein the PUFA product contains an amount of C18 fatty 5 acid impurities up to 1 wt %.2. The composition according to claim 1 , wherein the PUFA product contains an amount of C18 fatty acid impurities claim 1 , C18 fatty acid mono- claim 1 , di- and triglyceride and C18 fatty acid alkyl ester impurities up to 1 wt %.3. The composition according to claim 1 , wherein the PUFA product contains an amount of C18 fatty acid impurities up to 0.5 wt % or 0.25 wt %.4. The composition according to claim 2 , wherein the PUFA product contains an amount of C18 fatty acid impurities claim 2 , C18 fatty acid mono- claim 2 , di- and triglyceride and C18 fatty acid alkyl ester impurities up to 0.5 wt % or 0.25 wt %.5. The composition according to claim 1 , wherein the PUFA product is at least one ω-3 PUFA or a derivative thereof.6. The composition according to claim 5 , wherein the derivative of a PUFA is a PUFA in the form ...

METHOD OF MANUFACTURING BIO-DIESEL AND REACTOR

A reactor and process for the production of bio-diesel. The reactor includes one or more coiled reaction lines. The lines are positioned within a tank containing a heat transfer media such as molten salt, maintained at about 750° F. A pump circulates the media within the tank. An emulsion of alcohol; refined feed stock, including glycerides and/or fatty acids; and preferably water is pumped through the reaction lines at temperatures and pressures sufficient to maintain the alcohol in a super-critical state. The curvature of the coils, pump pulsing, and the flow rate of the emulsion keep the emulsion in a turbulent state while in the reactor, ensuring thorough mixing of the alcohol and feed stock. The alcohol reacts with the glycerides and fatty acids to form bio-diesel. The reaction is fast, efficient with regard to energy input and waste generation, and requires minimal alcohol. 1. A reactor comprising:a substantially fluid tight tank comprising an interior and an exterior;a heat transfer media positioned within said tank;a plurality of reaction lines positioned within said tank, wherein said plurality of reaction lines are in thermal communication with said heat transfer media and wherein said plurality of reaction lines are in fluid communication with one another and with said exterior of said tank;a manifold configured to regulate fluid communication between said plurality of reaction lines, wherein said manifold is configured to selectively allow fluid exiting a first of said plurality of reaction lines to flow to a second of said plurality of reaction lines or to divert fluid exiting said first of said plurality of reaction lines away from said second of said plurality of reaction lines, wherein said manifold is configured to divert a fluid having a density and exiting said first of said plurality of reaction lines out of said reactor if the density of the fluid has fallen by at least about 1 pound per cubic foot;at least one means for heating said heat ...

LIQUID-CRYSTAL MEDIUM

The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, 9. Liquid-crystalline medium according to claim 1 , characterised in that it additionally comprises one or more additive(s) selected from the group of the UV stabilisers claim 1 , dopants and antioxidants.10. Liquid-crystalline medium according to claim 1 , characterised in that it additionally comprises one or more polymerisable compounds.11. Process for the preparation of a liquid-crystalline medium according to claim 1 , characterised in that one or more compounds of the formula I are mixed with further liquid-crystalline compounds and optionally also with one or more additives and/or at least one polymerisable compound.12. An electro-optical device claim 1 , comprising a liquid-crystalline medium according to .13. An electro-optical device according to claim 12 , which device is selected from the group consisting of shutter glasses claim 12 , 3D applications claim 12 , TN claim 12 , PS-TN claim 12 , STN claim 12 , TN-TFT claim 12 , OCB claim 12 , IPS claim 12 , PS-IPS claim 12 , FFS claim 12 , PS-FFS and PS-VA-IPS displays.14. Electro-optical liquid-crystal display containing a liquid-crystalline medium according to . The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I,in whichin such a way that O atoms are not linked directly to one another, and in which, in addition, one or more H atoms may be replaced by halogen,Liquid crystals are used principally as dielectrics in display devices, since the optical properties of such substances can be modified by an applied voltage. Electro-optical devices based on liquid crystals are extremely well known to the person skilled in the art and can be based on various effects. Examples of such devices are cells having dynamic scattering, DAP (deformation of aligned phases) cells, guest/host cells, TN cells having a twisted nematic structure, STN (supertwisted ...

COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE

In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same. 1. A pharmaceutical composition comprising about 1 g of ethyl eicosapentaenoate , the pharmaceutical composition providing a mean plasma Cof about 154.9+/−49.4 μg/mL , a mean plasma AUCof about 2907+/−1160 μg·h/mL , a median plasma Tof about 5 hours , and a mean plasma Tof about 75.1+/−46.5 hours of ethyl eicosapentaenoate when administered orally twice per day to a human subject.2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further provides a mean plasma Cof about 101.0+/−50.4 μg/mL of ethyl eicosapentaenoate.3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further provides a mean plasma CL/F of about 776.4+/−256.9 mL/h of ethyl eicosapentaenoate.4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further provides a mean plasma V/F of about 79.8+/−62.6 L of ethyl eicosapentaenoate.5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further provides a mean RBC Cof about 42.3+/−14.0 μg/mL claim 1 , a mean RBC AUCof about 801.5+/−268.5 μg·h/mL claim 1 , a median RBC Tof about 12 hours claim 1 , and a mean RBC Tof about 683.8 hours of ethyl eicosapentaenoate.6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further provides a mean RBC Cof about 31.2+/−12.2 μg/mL of ethyl eicosapentaenoate.7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further provides a mean plasma Cof about 0.66+/−0.34 μg/mL claim 1 , a mean plasma AUCof about 6.9+/−3.1 μg·h/mL claim 1 , a median plasma Tof about 5 hours claim 1 , and a mean plasma Tof about 80.8+/−37.5 hours of unesterified eicosapentaenoic acid when administered orally twice per day to a human subject.8. The pharmaceutical composition of claim 1 , wherein the ...

Sorbic acid ester composition

The present invention is a method comprising the steps of a) applying a composition comprising a curing agent and a cure modulating additive to a substrate; and b) allowing the composition to cure. The curing agent is a sorbic acid ester or a sorbamide and the cure modulating agent is a reagent capable of modulating the rate of cure of the curing agent.

Composition containing eicosapentaenoic acid alkyl ester, and method for producing same

Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Ton or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.

FREE POLYUNSATURATED FATTY ACID-CONTAINING COMPOSITION AND MANUFACTURING METHOD THEREFOR

The present disclosure is: a free polyunsaturated fatty acid-containing composition, which comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, the content being at least 80.0% of the fatty acids in the composition, and satisfies at least one selected from a group consisting of conditions (1) and (2): (1) the content of conjugated unsaturated fatty acid is 1.0% or less of the fatty acids in the composition, and (2) the Gardner color is less than 3+; and a manufacturing method for the free polyunsaturated fatty acid-containing composition comprising the preparation of a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms, and hydrolysis of a reaction solution containing the prepared raw material composition, a lower alcohol, water and an alkali catalyst at a temperature of 10° C. or lower. 17-. (canceled)8. A manufacturing method of a free polyunsaturated fatty acid-containing composition , the method comprising:providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbons; andperforming hydrolysis treatment on a reaction solution containing the provided raw material composition, a lower alcohol, water, and an alkali catalyst in a temperature condition at 10° C. or lower.9. The manufacturing method according to claim 8 , wherein the polyunsaturated fatty acid in the raw material composition is a polyunsaturated fatty acid alkyl ester.10. The manufacturing method according to claim 8 , the method further comprising adding an acid in a reaction solution after the hydrolysis treatment to terminate the hydrolysis reaction claim 8 , a pH of the reaction solution after the acid addition being from pH 1.0 to 6.0.11. The manufacturing method according to claim 8 , wherein an amount of the lower alcohol in the reaction solution is from 0.9 equivalents to 32.0 equivalents relative to an amount of the fatty acids in the raw material ...

Lipids That Increase Insulin Sensitivity And Methods Of Using The Same

The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, Metabolic Syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects. 1. A method of decreasing pro-inflammatory signaling or increasing glucose uptake , glucose tolerance , insulin secretion , or insulin sensitivity in a cell , comprising contacting the cell with an agent that increases the level of one or more FAHFAs.2. A method of decreasing pro-inflammatory signaling or increasing glucose uptake , glucose tolerance , insulin secretion , or insulin sensitivity in a mammalian subject in need thereof , comprising administering to the subject a therapeutically effective amount of an agent that increases the level of one or more FAHFAs.3. The method of claim 2 , wherein the agent that increases the level of one or more FAHFAs is an exogenous FAHFA claim 2 , or a substrate of carboxyl ester lipase (CEL) or an inhibitor of CEL.4. The method of claim 2 , wherein the agent is a CHREBP expression product.5. The method of claim 2 , wherein the subject has Type-2 Diabetes.6. The method of claim 2 , wherein the pro-inflammatory signaling is dendritic cell maturation claim 2 , activation claim 2 , or proliferation; or macrophage cell maturation claim 2 , activation claim 2 , or proliferation.6. The method of claim 6 , wherein the dendritic cell maturation claim 6 , activation claim 6 , or proliferation comprises an increase in CD40+ claim 6 , CD80+ claim 6 , CD86+ claim 6 , MHCII+ cells claim 6 , or combinations thereof.87. The method of claim claim 6 , wherein the increased number of CD40+ claim 6 , CD80+ claim 6 , CD86+ claim 6 , or ...

PROCESS FOR OBTAINING FREE FATTY ACID AND/OR FATTY ACID ESTER

A process for obtaining free fatty acid and/or free fatty acid ester, including separating a liquid mixture containing the free fatty acid and/or the fatty acid ester by contacting a vapor of the liquid mixture in a column of a distillation apparatus with condensate formed from the vapor running downward. Heat and mass transfer takes place between the vapor and the condensate on column internals. The column has at least 10 theoretical plates and the separation is conducted with a pressure drop between the top and bottom of the column of Δp of ≥3.3 mbars. Appropriately, the liquid mixture, contains polyunsaturated fatty acid, preferably omega-6 or omega-3 fatty acid and/or alkyl monoesters and/or glycerol monoesters. In one embodiment the column has at least 30 theoretical plates and the separation is conducted with a pressure drop Δp between 3.5 mbar and 6 mbar. 110-. (canceled)11. A process for obtaining free fatty acid and/or fatty acid ester , comprising separating a liquid mixture containing the free fatty acid and/or the fatty acid ester by bringing rising vapor of the liquid mixture into contact in a column of a distillation apparatus with downcoming condensate formed from the vapor , wherein a mass and heat exchange takes place between the vapor and the condensate on internal components of the column , wherein the column comprises at least 10 theoretical plates , and the separating is carried out at a pressure drop between a top and a bottom of the column of Δp≥3.3 mbars.12. The process according to claim 11 , wherein the liquid mixture contains polyunsaturated fatty acid claim 11 , and/or alkyl and/or glycerol monoester.13. The process according to claim 12 , wherein the mixture contains omega-6 or omega-3 fatty acid.14. The process according to claim 11 , wherein the liquid mixture is produced from vegetable oil and/or from fish oil and/or from microorganisms.15. The process according to claim 11 , wherein the column comprises at least 30 theoretical plates ...

OPHTHALMIC FORMULATION

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein Ris a linear or branched C-Calkyl or a linear or branched C-Calkenyl with 1 to 4 double bonds; Ris a linear or branched C-Calkyl or a linear or branched C-Calkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier. 2. An ophthalmic formulation according to claim 1 , wherein HOOC—R— is selected from the group consisting of: capryl (C10:0) claim 1 , lauryl (C12:0) claim 1 , myristyl (C14:0) claim 1 , palmityl (C16:0) claim 1 , stearyl (C18:0) claim 1 , oleoyl (C18:1) claim 1 , linoleoyl (ω6) (C18:2) claim 1 , and linoleoyl (ω3) (C18:3).3. An ophthalmic formulation of claim 1 , wherein Ris linear or branched Calkyl or linear or branched Calkenyl with 1 or 2 double bonds.4. An ophthalmic formulation of claim 1 , wherein Ris linear or branched Calkenyl with 4 double bonds.6. (canceled)7. An ophthalmic formulation according to claim 1 , wherein the ophthalmologically acceptable carrier is claim 1 , or comprises claim 1 , water.8. An ophthalmic formulation of claim 1 , wherein the ophthalmic formulation further comprises an ophthalmologically acceptable excipient.9. An ophthalmic formulation according to claim 8 , wherein the ophthalmologically acceptable excipient is selected from the group consisting of demulcents claim 8 , emollients claim 8 , hypertonicity agents claim 8 , preservatives claim 8 , buffers and pH adjusting agents.10. An ophthalmic formulation of claim 1 , wherein the ophthalmic formulation is an oil in water emulsion.11. An ophthalmic formulation of claim 1 , wherein the ophthalmic formulation comprises liposomes.12. An ophthalmic formulation comprising a compound of formula (I) as defined in claim 1 , water claim 1 , and an emulsifying agent.13. An ophthalmic formulation comprising a compound of formula (I) as defined in claim 1 , water claim 1 , and one or more ophthalmologically acceptable excipients selected from the group consisting of ...

SYSTEMS AND METHODS FOR PRODUCTION OF MIXED FATTY ESTERS

Disclosed herein are various embodiments regarding the production of fatty acid methyl esters. Disclosed herein are various embodiments regarding the use of methanol compositions for the production of fatty esters. 141-. (canceled)42. A genetically modified bacterial cell for production of a fatty ester , comprising an exogenous nucleic acid sequence encoding an alcohol forming polypeptide and an alcohol acetyltransferase polypeptide capable of catalyzing a conversion of a thioester and an alcohol , wherein said bacterial cell converts a renewable carbon source into a fatty ester.43. The bacterial cell of claim 42 , wherein said alcohol acetyltransferase polypeptide is alcohol acetyltransferase of EC 2.3.1.84.44. The bacterial cell of claim 43 , wherein said alcohol forming polypeptide is fatty alcohol forming acyl-CoA reductase of EC 1.1.1.*.45. The bacterial cell of claim 44 , wherein said cell is further genetically modified to express an exogenous nucleic acid sequence encoding acyl-CoA synthase.46. The bacterial cell of claim 45 , wherein said cell is further genetically modified to express an exogenous nucleic acid sequence encoding a thioesterase.47. The bacterial cell of claim 42 , wherein said alcohol forming polypeptide is acyl-CoA reductase of EC 1.1.1.50.48. The bacterial cell of claim 47 , wherein said cell is further genetically modified to express an exogenous nucleic acid sequence encoding acyl-CoA synthase.49. The bacterial cell of claim 48 , wherein said cell is further genetically modified to express an exogenous nucleic acid sequence encoding a thioesterase.50. The bacterial cell of claim 49 , wherein said cell is further genetically modified to express an exogenous nucleic acid sequence encoding an alcohol dehydrogenase of E.C. 1.1.1.1.51Escherichia coli, Arthrobacter, Rhodotorula glutinins, Acinetobacter, Botryococcus braunii, Vibrio furnissii, Micrococcus leuteus, Stenotrophomonas maltophilia, Bacillus subtilis. The bacterial cell of claim 42 ...

LIPID COMPRISING DOCOSAPENTAENOIC ACID

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid. 1. Extracted plant lipid , comprising fatty acids in an esterified form , the fatty acids comprising oleic acid , palmitic acid , ω6 fatty acids which comprise linoleic acid (LA) , ω3 fatty acids which comprise α-linolenic acid (ALA) and docosapentaenoic acid (DPA) , and optionally one or more of stearidonic acid (SDA) , eicosapentaenoic acid (EPA) , and eicosatetraenoic acid (ETA) , wherein the level of palmitic acid in the total fatty acid content of the extracted lipid is between about 2% and 16% , and wherein the level of myristic acid (C14:0) in the total fatty acid content of the extracted lipid , if present , is less than 1% , and wherein the level of DPA in the total fatty acid content of the extracted lipid is between 7% and 35%.2. The extracted plant lipid of which has one or more of the following featuresi) the level of palmitic acid in the total fatty acid content of the extracted plant lipid is between about 2% and 15%, or between about 3% and about 10%,ii) the level of myristic acid (C14:0) in the total fatty acid content of the extracted plant lipid is about 0.1%,iii) the level of oleic acid in the total fatty acid content of the extracted plant lipid is between about 1% and about 30%, between about 3% and about 30%, between about 6% and about 30%, between 1% and about 20%, between about 30% and about 60%, about 45% to about 60%, about 30%, or between about 15% and about 30%,iv) the level of linoleic acid (LA) in the total fatty acid content of the extracted plant lipid is between about 4% and about 35%, between about 4% and about 20%, between about 4% and about 17%, or between about 5% and about 10%,v) the level of α-linolenic acid (ALA) in the total fatty acid content of the extracted plant lipid is between about 4% and about 40%, between about 7% and about 40%, between about 10% and about 35%, ...

COIX SEED OIL CONTAINING 11 TRIGLYCERIDES, AND PHARMACEUTICAL PREPARATION AND USE THEREOF

The present invention relates to seed oil extracted from , pharmaceutical preparations thereof, and the use thereof in the treatment of tumors. Specifically, the seed oil contains 11 triglyceride ingredients in the following mass percentages: trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76% and 1-palmitin-2,3-diolein 8.06-11.58%, 1-olein-2-linolein-3-stearin 1.37-1.97%, 1,3-dipalmitin-2-olein 1.52-2.19% and 1,2-diolein-3-stearin 1.29-1.86%. 110-. (canceled)11Coix. A seed oil , comprising 11 triglyceride ingredients in the following mass percentages: trilinolein 4.87-6.99% , 1-olein-2 ,3-dilinolein 13.00-18.69% , 1-palmitin-2 ,3-dilinolein 5.25-7.54% , 1 ,3-diolein-2-linolein 13.23-19.02% , 1-palmitin-2-linolein-3-olein 10.26-14.75% , 1 ,3-dipalmitin-2-linolein 2.28-3.28% , triolein 14.44-20.76% , 1-palmitin-2 ,3-diolein 8.06-11.58% , 1-olein-2-linolein-3-stearin 1.37-1.97% , 1 ,3-dipalmitin-2-olein 1.52-2.19% and 1 ,2-diolein-3-stearin 1.29-1.86%.12Coix. The seed oil of claim 11 , having the following physicochemical constants based on the fatty oil detection: specific gravity at 20° C. 0.917-0.920 claim 11 , refractive index at 20° C. 1.471-1.474 claim 11 , acid value <0.2 claim 11 , iodine value 100-106 claim 11 , saponification value 188-195.13Coix. The seed oil of claim 11 , wherein said triglyceride ingredients are in the following mass percentages: trilinolein 5.47-6.69% claim 11 , 1-olein-2 claim 11 ,3-dilinolein 14.63-17.88% claim 11 , 1-palmitin-2 claim 11 ,3-dilinolein 5.90-7.21% claim 11 , 1 claim 11 ,3-diolein-2-linolein 14.88-18.19% claim 11 , 1-palmitin-2-linolein-3-olein 11.55-14.11% claim 11 , 1 claim 11 ,3-dipalmitin-2-linolein 2.57-3.14% claim 11 , triolein 16.25-19.86% claim 11 , 1-palmitin-2 claim 11 ,3-diolein 9.07-11.08% claim 11 , 1-olein-2-linolein-3- ...

LIPID COMPOSITIONS COMPRISING TRIACYLGLYCEROL WITH LONG-CHAIN POLYUNSATURATED FATTY ACIDS

The present invention relates to lipid comprising docosapentaenoic acid and/or docosahexaenoic acid wherein the docosapentaenoic acid and/or docosahexaenoic acid may be preferentially esterified at the sn- position of triacylglycerol, and processes for producing and using the lipid. 1. Extracted plant lipid , comprising fatty acids in an esterified form , the fatty acids comprising oleic acid , palmitic acid , ω6 fatty acids which comprise linoleic acid (LA) , ω3 fatty acids which comprise α-linolenic acid (ALA) and docosahexaenoic acid (DHA) , and optionally one or more of stearidonic acid (SDA) , eicosapentaenoic acid (EPA) , docosapentaenoic acid (DPA) and eicosatetraenoic acid (ETA) , wherein the level of palmitic acid in the total fatty acid content of the extracted lipid is between about 2% and 16% , and wherein the level of myristic acid (C14:0) in the total fatty acid content of the extracted lipid , if present , is less than 1% , and wherein the level of DHA in the total fatty acid content of the extracted lipid is between 20.1% and 35%.2. The extracted plant lipid of which has one or more of the following featuresi) the level of palmitic acid in the total fatty acid content of the extracted plant lipid is between about 2% and 15%, or between about 3% and about 10%,ii) the level of myristic acid (C14:0) in the total fatty acid content of the extracted plant lipid is about 0.1%,iii) the level of oleic acid in the total fatty acid content of the extracted plant lipid is between about 1% and about 30%, between about 3% and about 30%, between about 6% and about 30%, between 1% and about 20%, between about 30% and about 60%, about 45% to about 60%, about 30%, or between about 15% and about 30%,iv) the level of linoleic acid (LA) in the total fatty acid content of the extracted plant lipid is between about 4% and about 35%, between about 4% and about 20%, between about 4% and about 17%, or between about 5% and about 10%,v) the level of α-linolenic acid (ALA) in ...

Plant Extract Compositions for Forming Protective Coatings

Described herein are methods of preparing cutin-derived monomers, oligomers, or combinations thereof from cutin-containing plant matter. The methods can include heating the cutin-derived plant matter in a solvent at elevated temperature and pressure. In some preferred embodiments, the methods can be carried out without the use of additional acidic or basic species.

COMPOSITION CONTAINING EICOSAPENTAENOIC ACID ALKYL ESTER, AND METHOD FOR PRODUCING SAME

Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.

PROCESS FOR PREPARING A FORMYLALKENYL ALKOXYMETHYL ETHER COMPOUND AND PROCESSES FOR PREPARING CONJUGATED DIENE COMPOUNDS FROM THE SAME

The present invention provide for preparing a formylalkenyl alkoxymethyl ether compound of the following general formula (2): RCHOCHO(CH)CH═CHCHO (2), wherein Rrepresents a hydrogen atom, an n-alkyl group having 1 to 9 carbon atoms, or a phenyl group; and “a” represents an integer of 1 to 10, the process comprising: hydrolyzing a dialkoxyalkenyl alkoxymethyl ether compound of the following general formula (1): RCHOCHO(CH)CH═CHCH(OR)(OR) (1), wherein Rand Rrepresent, independently of each other, a monovalent hydrocarbon group having 1 to 15 carbon atoms, or Rand Rmay form together a divalent hydrocarbon group, R-R, having 2 to 10 carbon atoms; and Rand “a” are as defined above, in the presence of an acid while removing an alcohol compound thus generated to form the formylalkenyl alkoxymethyl ether compound (2). 1. A process for preparing a formylalkenyl alkoxymethyl ether compound of the following general formula (2):{'br': None, 'sup': '3', 'sub': 2', '2', '2', 'a, 'RCHOCHO(CH)CH═CHCHO\u2003\u2003(2)'}{'sup': '3', 'wherein Rrepresents a hydrogen atom, an n-alkyl group having 1 to 9 carbon atoms, or a phenyl group, and “a” represents an integer of 1 to 10,'} {'br': None, 'sup': 3', '1', '2, 'sub': 2', '2', '2', 'a, 'RCHOCHO(CH)CH═CHCH(OR)(OR)\u2003\u2003(1)'}, 'hydrolyzing a dialkoxyalkenyl alkoxymethyl ether compound of the following general formula (1), 'the process comprising{'sup': 1', '2', '1', '2', '1', '2', '3, 'wherein Rand Rrepresent, independently of each other, a monovalent hydrocarbon group having 1 to 15 carbon atoms, or Rand Rmay form together a divalent hydrocarbon group, R-R, having 2 to 10 carbon atoms; and Rand “a” are as defined above,'}in the presence of an acid, while removing an alcohol compound thus generated to form the formylalkenyl alkoxymethyl ether compound (2).2. The process for preparing the formylalkenyl alkoxymethyl ether compound (2) according to claim 1 , wherein the acid is formic acid claim 1 , hydrochloric acid or a combination ...

COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF INFLAMMATORY, DEGENERATIVE, AND NEURODEGENERATIVE DISEASES

This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions. 2. The composition of claim 1 , wherein n is a number selected from a group consisting of 0 to 13.3. The composition of claim 1 , wherein n is selected from a group consisting of 1 claim 1 , 3 claim 1 , 5 claim 1 , 7 claim 1 , 9 claim 1 , 11 or 13.4. The composition of claim 1 , wherein n is selected from a group consisting of 0 claim 1 , 2 claim 1 , 4 claim 1 , 6 claim 1 , 8 claim 1 , 10 or 12.6. The compound of claim 5 , wherein n is a number selected from a group consisting of 0 to 13.7. The compound of claim 5 , wherein n is selected from a group consisting of 1 claim 5 , 3 claim 5 , 5 claim 5 , 7 claim 5 , 9 claim 5 , 11 or 13.8. The compound of claim 5 , wherein n is selected from a group consisting of 0 claim 5 , 2 claim 5 , 4 claim 5 , 6 claim 5 , 8 claim 5 , 10 or 12.9. The compound of claim 5 , wherein n is 9 or 11.10. The compound of claim 5 , wherein the R group is methyl or ethyl.11. The compound of claim 5 , wherein the R group is a metal cation selected from a group consisting of sodium claim 5 , potassium claim 5 , magnesium claim 5 , zinc claim 5 , and calcium cation.14. The compound of claim 13 , wherein n is a number selected from a group consisting of 0 to 13.15. The compound of claim 13 , wherein n is selected from a group consisting of 1 claim 13 , 3 claim 13 , 5 claim 13 , 7 claim 13 , 9 claim 13 , 11 or 13.16. The compound of claim 13 , wherein n is selected from a group consisting of 0 claim 13 , 2 claim 13 , 4 claim 13 , 6 claim 13 , 8 claim 13 , 10 ...

NEW LIPOPHENOL COMPOUNDS AND USES THEREOF

The present invention relates to a compound of formula (I) wherein:—i is 0 or 1; j is 0 or 1; k is 0 or 1;—Rand Rare in particular H, (C-C)alkyl, or a group of formula C(O)R;—R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms;—Ris H and k=0 when j=1; or, when j=0, Ris —C(O)R or -L-C(O)R;—L, U and L″ are linkers; wherein, when j=0, at least one of the groups R; Rand Rcomprises a radical R. 119-. (canceled)21. The method of claim 20 , wherein claim 20 , in formula (I) claim 20 , when j=0 claim 20 , at most one of the groups R claim 20 , Rand Ris H.24. The method of claim 23 , wherein claim 23 , in formula (I-2) claim 23 , Ris an alkyl group.29. The method of claim 20 , wherein claim 20 , in formula (I) claim 20 , Ris a (C-C)alkyl group.30. The method of claim 20 , wherein claim 20 , in formula (I) claim 20 , Ris a (C-C)alkyl group31. The method of claim 20 , wherein claim 20 , in formula (I) claim 20 , Ris an isopropyl group.32. The method of claim 20 , wherein claim 20 , in formula (I) claim 20 , R is a linear or branched alkyl group claim 20 , possibly interrupted by one or several double bonds claim 20 , comprising from 19 to 23 carbon atoms.33. The method of claim 20 , wherein claim 20 , in formula (I) claim 20 , R is a linear or branched alkyl group claim 20 , possibly interrupted by one or several double bonds claim 20 , comprising from 19 to 23 carbon atoms claim 20 , and wherein one or several hydrogen atoms are replaced by deuterium atoms.34. The method of claim 20 , wherein claim 20 , in formula (I) claim 20 , R is a linear or branched alkyl group claim 20 , interrupted by at least one double bond claim 20 , comprising from 19 to 21 carbon atoms.37. The method of claim 20 , wherein the pathology involving carbonyl and oxidative stress is chosen from the group consisting of: inflammatory and infectious diseases claim 20 , cardiovascular diseases claim 20 , metabolic diseases claim 20 , cancer claim 20 , retinal pathologies claim 20 ...

OPHTHALMIC FORMULATION

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I): 2. An ophthalmic formulation according to claim 1 , wherein HOOC—R— is selected from the group consisting of: capryl (C10:0) claim 1 , lauryl (C12:0) claim 1 , myristyl (C14:0) claim 1 , palmityl (C16:0) claim 1 , stearyl (C18:0) claim 1 , oleoyl (C18:1) claim 1 , linoleoyl (ω6) (C18:2) claim 1 , and linoleoyl (ω3) (C18:3).3. An ophthalmic formulation of claim 1 , wherein Ris linear or branched Calkyl or linear or branched Calkenyl with 1 or 2 double bonds.4. An ophthalmic formulation of claim 1 , wherein Ris linear or branched Calkenyl with 4 double bonds.6. An ophthalmic formulation according to claim 1 , wherein the compound of formula (I) is (O-oleoyl)-16-hydroxypalmitic acid.7. An ophthalmic formulation according to claim 1 , wherein the ophthalmologically acceptable carrier is claim 1 , or comprises claim 1 , water.8. An ophthalmic formulation of claim 1 , wherein the ophthalmic formulation further comprises an ophthalmologically acceptable excipient.9. An ophthalmic formulation according to claim 8 , wherein the ophthalmologically acceptable excipient is selected from the group consisting of demulcents claim 8 , emollients claim 8 , hypertonicity agents claim 8 , preservatives claim 8 , buffers and pH adjusting agents.10. An ophthalmic formulation of claim 1 , wherein the ophthalmic formulation is an oil-in-water emulsion.11. An ophthalmic formulation of claim 1 , wherein the ophthalmic formulation comprises liposomes.12. An ophthalmic formulation comprising a compound of formula (I) as defined in claim 1 , water claim 1 , and an emulsifying agent.13. An ophthalmic formulation comprising a compound of formula (I) as defined in claim 1 , water claim 1 , and one or more ophthalmologically acceptable excipients selected from the group consisting of polyethylene glycol claim 1 , propylene glycol claim 1 , glycerin claim 1 , polyvinyl alcohol claim 1 , povidone claim 1 , ...

COSMETIC COMPOSITION OBTAINED BY ESTERIFICATION OF AMYL ALCOHOL OR AN ISOMER THEREOF AND A NATURAL VEGETABLE OIL FATTY ACID

Disclosed is a cosmetic composition containing, as an active ingredient, an ester oil obtained by the bonding and esterification of amyl alcohol or an isomer thereof and a fatty acid derived from a natural vegetable oil such as olive oil or coconut oil. The ester oil increases the viscosity and imparts stability to cosmetics while also having a far better moisturizing ability and a lighter feeling in use than silicone oil, and the invention therefore allows a naturally derived ester oil, which is relatively friendly to the human body, to be used as a fundamental base component of a cosmetic composition, in complete or partial substitution for silicone oil which has been used on account of the shortcomings of existing synthetic ester oils. 1. A cosmetic composition comprising , as an active ingredient , ester oil obtained by mixing and esterification of amyl alcohol or an isomer thereof with fatty acids derived from natural vegetable oil.2. The cosmetic composition according to claim 1 , wherein the isomer is any one isomer selected from the group consisting of 3-methyl-1-butanol(isoamyl alcohol) claim 1 , 2-methyl-1-butano 1 claim 1 ,2 claim 1 ,2-dimethyl-1-propanol claim 1 , 3-pentanol claim 1 , 2-pentano 1 claim 1 ,3-methyl-2-butano 1 claim 1 , and 2-methyl-2-butanol.3. The cosmetic composition according to claim 1 , wherein the natural vegetable oil is olive oil or coconut oil.4. The cosmetic composition according to claim 3 , wherein the fatty acids derived from olive oil is at least one selected from the group consisting of palmitic acid claim 3 , palmitoleic acid claim 3 , stearic acid claim 3 , oleic acid claim 3 , linoleic acid and linolenic acid.5. The cosmetic composition according to claim 3 , wherein the fatty acids derived from coconut oil is at least one selected from the group consisting of caprylic acid claim 3 , capric acid claim 3 , lauric acid claim 3 , myristic acid claim 3 , palmitic acid claim 3 , stearic acid and oleic acid.6. The cosmetic ...

Inhibitor Combination for Lithium Salt-Catalyzed Transesterification Process and Method for Removing Lithium Salt

A process to form a composition comprising an asymmetrical polyene, the asymmetrical polyene comprising an “α,β unsaturated-carbonyl end” and a “C—C double bond end,” the process comprising: reacting an alkene- or polyene-containing alcohol with an alkyl ester of an α,β unsaturated carboxylic acid in the presence of at least the following components A) through C) to form a solution comprising an asymmetrical polyene: A) a lithium salt; B) a component selected from the group consisting of hydroquinone, an alkyl-substituted phenol, a substituted alkyl-substituted phenol, an alkyl-substituted hydroquinone, a substituted alkyl-substituted hydroquinone, and combinations thereof; and C) an N-oxyl-containing compound; wherein the “α,β unsaturated-carbonyl end” of the asymmetrical polyene is selected from the group consisting of structures a) through c), as described herein, and wherein the “C—C double bond end” of the asymmetrical polyene is selected from the group consisting of structures 1) through 17), as described herein. 2. The process of claim 1 , wherein the lithium salt has the structure LiX claim 1 , wherein n is 1 or 2; and X is selected from the group consisting of hydroxide claim 1 , oxide claim 1 , halide claim 1 , carbonate claim 1 , bicarbonate claim 1 , alkoxide claim 1 , alkonate claim 1 , alkenoate claim 1 , phenoxide claim 1 , sulfate claim 1 , bisulfate claim 1 , sulfonate claim 1 , phosphate claim 1 , phosphonate claim 1 , perchlorate claim 1 , nitrate claim 1 , or any other stable anionic moieties capable of forming ionic salts.3. The process of claim 1 , wherein component A) has the structure LiX claim 1 , wherein n is 1 or 2; and X is selected from the group consisting of OH claim 1 , O claim 1 , a halide claim 1 , OR claim 1 , CO claim 1 , HCO claim 1 , and R′CO; wherein R is selected from a C1-C8 straight chain or branched alkyl group or from an aryl group; wherein R′ is selected from either a C1-C8 straight chain or branched alkyl group claim 1 , ...

Preparation of a sorbate ester

The present invention is a process for preparing a hydroxyalkyl sorbate comprising the steps of of: a) contacting together in a reaction vessel a solvent, sorbic acid, a transition metal halide catalyst, an anti-oxidant, and an alkylene oxide under conditions sufficient to form the hydroxyalkyl sorbate; b) removing the solvent in vacuo, wherein the anti-oxidant is characterized by the following formula or a carboxylic acid salt thereof: wherein Y, x, and R 1 are defined herein. The process of the present invention provides a convenient way of preparing hydroxyalkyl sorbates in high yield and purity without complicated workup steps.

PREPARATION OF A SORBATE ESTER

The present invention is a process for preparing a sorbate ester comprising the steps of: a) contacting together in a reaction vessel a first organic solvent, sorbic acid, a catalytic amount of TiC14, an anti-oxidant, and an alkylene oxide under conditions sufficient to form a mixture of the sorbate ester and residual water-soluble impurities; then b) separating the sorbate ester from the residual water-soluble impurities by washing. Sorbate esters can be prepared in an efficient and cost-effective manner by the process of the present invention. 1. A process for preparing a sorbate ester comprising the steps of: a) contacting together in a reaction vessel a first organic solvent , sorbic acid , a catalytic amount of a titanate catalyst , an anti-oxidant , and an alkylene oxide selected from the group consisting of C-Calkylene oxides , glycidyl methacrylates , glycidyl acrylates , diglycidyl ethers of bisphenols , alkylene glycol diglycidyl ethers , polyalkylene glycol diglycidyl ethers , alkane diol diglycidyl ethers , tri- and tetraglycidyl ethers , and hydoxylalkyl alkylene oxides under conditions sufficient to form a mixture of the sorbate ester and residual water-soluble impurities; then b) separating the sorbate ester from the residual water-soluble impurities by washing; wherein the anti-oxidant is a hindered amine , a hindered N-oxide , a phenothiazine , or a phenol , or a combination thereof.2. The process of wherein the solvent claim 1 , sorbic acid claim 1 , and the titanate catalyst are contacted together prior to the introduction of the alkylene oxide.3. The process of wherein the alkylene oxide is ethylene oxide claim 1 , propylene oxide claim 1 , butylene oxide claim 1 , bisphenol A diglycidyl ether claim 1 , ethylene glycol diglycidyl ether claim 1 , polyethylene glycol diglycidyl ethers claim 1 , propylene glycol diglycidyl ether claim 1 , polypropylene glycol diglycidyl ethers claim 1 , butylene glycol diglycidyl ether claim 1 , polybutlene glycol ...

Lipid comprising docosapentaenoic acid

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.

BIODEGRADABLE COATINGS AND PAINTS

Disclosed herein are biodegradable coating and paint compositions comprising 1,3-propanediol, wherein the 1,3-propanediol in said biodegradable composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein upon biodegradation, the biologically-derived 1,3-propanediol contributes no anthropogenic CO2 emissions to the atmosphere. 1. A biodegradable composition comprising 1 ,3-propanediol and an ingredient , wherein said 1 ,3-propanediol has a bio-based carbon content of at least 1% , wherein the bio-based carbon has a C-14/C-12 isotope ratio in range of from 1:0 to greater than 0:1 , wherein said composition has a lower anthropogenic COemission profile as compared to a biodegradable composition comprising a 1 ,3-propanediol with a bio-based carbon content of 0% and wherein said composition is selected from the group consisting of coatings , paints , and inks.2. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol makes up about 1% to about 50% of the composition by weight.3. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol has at least 5% biobased carbon.4. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol has at least 10% biobased carbon.5. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol has at least 25% biobased carbon.6. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol has at least 50% biobased carbon.7. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol has at least 75% biobased carbon.8. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol has at least 90% biobased carbon.9. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol has at least 99% biobased carbon.10. The biodegradable composition of wherein the 1 claim 1 ,3-propanediol has 100% biobased carbon.11. The biodegradable composition of wherein the 1 claim 1 ,3- ...

HIGHLY UNSATURATED FATTY ACID OR HIGHLY UNSATURATED FATTY ACID ETHYL ESTER WITH REDUCED ENVIRONMENTAL POLLUTANTS, AND METHOD FOR PRODUCING SAME

A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester that has been produced using as a feedstock oil a fat or oil that contains highly unsaturated fatty acids as constituent fatty acids and which has been reduced in the contents of environmental pollutants, wherein among the dioxins contained, polychlorinated dibenzoparadioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) are contained in amounts of less than 0.05 pg-TEQ/g and coplanar PCBs (Co-PCBs) in amounts of less than 0.03 pg-TEQ/g. Also disclosed is a method for producing the highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester by the steps of removing free fatty acids and environmental pollutants by thin-film distillation from a feedstock oil, ethyl esterifying the resulting fat or oil, and refining the same by rectification and column chromatography. 120-. (canceled)21. A composition comprising a highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester which has been produced using as a feedstock oil or fat that contains (i) the highly unsaturated fatty acid as a constituent fatty acid , and (ii) a brominated flame retardant ,wherein the composition comprises a brominated flame retardant, and wherein the amount of the brominated flame retardant has been reduced to such a level that the amount of BDE-47 is less than 0.18 ng/g, the amount of BDE-100 is less than 0.03 ng/g, the amount of BDE-49 is less than 0.05 ng/g, or the amount of BDE-99 is less than 0.05 ng/g.22. The composition according to claim 21 , wherein the concentration of highly unsaturated fatty acids in the sum of fatty acids is at least 80 area % claim 21 , at least 85 area % claim 21 , at least 90 area % claim 21 , at least 95 area % claim 21 , or at least 96 area %.23. The composition according to claim 21 , wherein the fat or oil is fish oil claim 21 , krill oil claim 21 , marine mammal oil claim 21 , or microorganism oil.24. The composition according to claim 21 , ...

AGENTS FOR MAINTAINING UNDIFFERENTIATED STATE AND PROMOTING PROLIFERATION OF STEM CELLS

An object of the present invention is to find a novel substance that is capable of efficiently promoting the proliferation of stem cells while maintaining the undifferentiated state thereof and to provide the substance as an agent for maintaining the undifferentiated state of stem cells or an agent for promoting the proliferation of stem cells. Another object of the present invention is to provide an agent for treating a wound that has a wound healing effect on the skin and is readily available in the field of skin regenerative medicine or cosmetic treatment, and safe and inexpensive. The present invention relates to an agent for maintaining the undifferentiated state or promoting the proliferation of stem cells or an agent for treating a wound, comprising, as an active ingredient, one or a mixture of two or more of fatty acid glycerides represented by the following general formula (I): 4. The agent according to any of to , wherein the unsaturated fatty acid is selected from the group consisting of docosahexaenoic acid , eicosapentaenoic acid , arachidonic acid , α-linolenic acid , γ-linolenic acid , linoleic acid , and oleic acid.5. A cosmetic product comprising the agent according to any of to .6. A pharmaceutical product or quasi drug comprising the agent according to any of to .7. A food or drink comprising the agent according to any of to .11. The method according to any of to , wherein the unsaturated fatty acid is an unsaturated fatty acid selected from the group consisting of docosahexaenoic acid , eicosapentaenoic acid , arachidonic acid , α-linolenic acid , γ-linolenic acid , linoleic acid , and oleic acid. The present invention relates to an agent for maintaining the undifferentiated state or promoting the proliferation of stem cells or for treating a wound and a method for promoting the proliferation of stem cells and a method for maintaining the undifferentiated state of stem cells.Tissue in vertebrates (in particular mammals) responds to cell or organ ...

Omefibrates for Treating Dyslipidemia and Cardiovascular Disease

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, Alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (PPARs). 3. The method of wherein the compound is ≧90% chemical purity.4. The method of having as its active ingredient one or more compounds of Formula (I) as defined in .5. The method of wherein the active ingredient is in a formulation in the form of a solution for injection claim 1 , ampoule claim 1 , hard or soft gelatin capsule or tablet claim 1 , or as a sustained release formulation.6. The method of to treat hypertriglyceridemia claim 1 , Type2 diabetes claim 1 , or metabolic syndrome in persons needing such treatment by administering to such persons an effective amount of the active ingredient in the formulation.7. The method of to treat metabolic syndrome wherein Rin Formula (I) is the metformin cation.8. The method of claim 6 , wherein the triglycerides levels in such persons needing treatment are in a range of from >100 mg/dl claim 6 , to >500 mg/dl.9. The method of for the treatment of early stages of Alzheimer's disease in persons needing such treatment by administering to such person an effective amount of the active ingredient of the formulation.10. The method of claim 6 , wherein the effective amount is from about 0.05 to about 5 g/day administered as 1-4 doses/day.11. (canceled) The present invention relates to novel Omefibrates that are fibric acid type derivatives of omega-3 polyunsaturated acids (fatty acids) used for treating hypertriglyceridemia, cardiovascular disease, metabolic syndrome, Type2 diabetes, obesity, cancer, renal anemia, Alzheimer's disease; and for modulating activity of peroxisome proliferator-activated receptors (PPARs).Coronary heart disease (CHD) continues to be a leading cause of impaired quality of life and ...

Omefibrates for Treating Dyslipidemia and Cardiovascular Disease

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, Alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (PPARs). 3. The compound of wherein the compound is ≦90% chemical purity.4. A pharmaceutical formulation having as its active ingredient one or more compounds of Formula (I) as defined in and pharmaceutically-acceptable salts claim 1 , adjuvants claim 1 , binders claim 1 , desiccants claim 1 , diluents and excipients.5. The pharmaceutical formulation of in the form of a solution for injection claim 4 , ampoule claim 4 , hard or soft gelatin capsule or tablet claim 4 , or as a sustained release formulation.6. The pharmaceutical formulation of to treat hypertriglyceridemia claim 4 , Type2 diabetes claim 4 , or metabolic syndrome in persons needing such treatment by administering to such persons an effective amount of the formulation.7. The pharmaceutical formulation of to treat metabolic syndrome wherein Ris the metformin cation.8. The pharmaceutical formulation of claim 6 , wherein the triglycerides levels in such persons needing treatment are in a range of from >100 mg/dl claim 6 , to >500 mg/dl.9. The pharmaceutical formulation of for the treatment of and to slow down the progression of early stages of Alzheimer's disease in persons needing such treatment by administering to such person an effective amount of the formulation.10. The pharmaceutical formulation of claim 6 , wherein the effective amount is from about 0.05 to about 5 g/day administered as 1-4 doses/day.11. A method for treating hypertriglyceridemia claim 4 , cardiovascular disease claim 4 , metabolic syndrome claim 4 , Type2 diabetes claim 4 , obesity claim 4 , cancer claim 4 , renal anemia claim 4 , or Alzheimer's disease in a person in need of such treatment by administering an effective ...

POLYOL ESTERS OF METATHESIZED FATTY ACIDS AND USES THEREOF

Polyol esters of metathesized fatty acids are generally disclosed herein. Methods of using such compounds, for example, as cleaning agents, solvents, and coalescents for paints and coatings, are also disclosed. 131-. (canceled)33. The composition of claim 32 , wherein the film-forming polymer is a natural latex claim 32 , a synthetic latex claim 32 , or a mixture thereof.34. The composition of claim 33 , where the film-forming polymer is a synthetic latex.35. The composition of claim 34 , where the synthetic latex is an acrylic polymer claim 34 , polyvinyl acetate claim 34 , polyvinyl chloride claim 34 , styrene-butadiene rubber claim 34 , acrylonitrile-butadiene rubber claim 34 , or a mixture thereof.36. The composition of claim 32 , wherein the weight-to-weight ratio of film-forming polymer to compound ranges from 5:1 to 200:1.3741-. (canceled)42. The composition of claim 32 , wherein the composition has no more than 0.5 kg/L of volatile organic compounds (VOCs) claim 32 , as measured by Method 24 of the United States Environmental Protection Agency.4349-. (canceled)50. The composition of claim 32 , wherein Ris —H.51. The compound of claim 32 , wherein Ris —CH—CH.52. The compound of claim 32 , wherein Ris —(Calkylene)-OH.53. The compound of claim 52 , wherein Ris —(CH)—OH claim 52 , —(CH)—OH claim 52 , —(CH)—OH claim 52 , —(CH)—OH claim 52 , —(CH)—OH claim 52 , —CH(OH)—CH claim 52 , —CH—CH(OH)—CH claim 52 , —CH(CH)—CH—OH claim 52 , —CH—CH(CH)—CH—OH claim 52 , or —CH—C(CH)—CH(OH)—CH(CH).54. The compound of claim 53 , wherein Ris —(CH)—OH.55. The compound of claim 53 , wherein Ris —(CH)—OH.56. The compound of claim 53 , wherein Ris —(CH)—OH.57. The compound of claim 53 , wherein Ris —CH(OH)—CH.58. The compound of claim 53 , wherein Ris —CH—CH(OH)—CH.59. The compound of claim 53 , wherein Ris —CH(CH)—CH—OH.60. The compound of claim 53 , wherein Ris —CH—CH(CH)—CH—OH.61. The compound of claim 53 , wherein Ris —CH—C(CH)—CH(OH)—CH(CH). The present application is a ...

1-HALOALKADIENE AND A PROCESS FOR PREPARING THE SAME AND A PROCESS FOR PREPARING (9e, 11z)-9,11-HEXADECADIENYL ACETATE

A process to prepare (9E,11Z)-9,11-hexadecadienyl acetate with a good yield and high purity of the general formula (1): CH—(CH)—CH═CH—CH═CH—(CH)—X.=The process includes a step of conducting a Wittig reaction between a haloalkenal of the general formula (2): OHC—CH═CH—(CH)—X, and a triarylphosphonium pentylide of the general formula (3): CH—(CH)—CH—PAr, to obtain the 1-haloalkadiene, and the use of a (7E,9Z)-1-halo-7,9-tetradecadiene obtained by the process for a process of preparing (9E, 11Z)-9,11-hexadecadienyl acetate. The present invention relates to a process for preparing (9E,11Z)-9,11-hexadecadienyl acetate from a 1-haloalkadiene.Pecan nut casebearer () is a serious insect pest against pecans, which tunnels into pecan nuts and feeds in the nuts. The use of insecticides for pest control on the pecan nut casebearer may lead to outbreak of secondary insect pests, such as aphids, mites and leaf-miner flies, because the insecticides also kill natural enemies of such secondary insect pests. Therefore, a large hope is placed on mating disruption using a sex pheromone.(9E,11Z)-9,11-Hexadecadienal and (9E,11Z)-9,11-hexadecadienyl acetate were identified as components of natural sex pheromones of the pecan nut casebearer (Non-Patent Literatures 1 (J. G. Millar et al., Bioorg. Med. Chem. 1996, 4, 331-339) and 2 (M. K. Harris et al., J. Econ. Entomol. 2008, 101, 769-776)). Harris et al. describes a process for preparing (9E,11Z)-9,11-hexadecadienyl acetate, in which (1E)-1-chloro-1-octen-3-yne, which has been obtained by the Sonogashira coupling of (E)-1,2-dichloroethene with 1-hexyne, is subjected to the Kochi-Fürstner coupling with 1-(tetrahydropyranyloxy)-8-bromooctane derived from 1,8-octanediol to obtain (9E)-1-(tetrahydropyranyloxy)-9-hexadecen-11-yne, followed by hydroboration and subsequent protonation, removal of a protecting tetrahydropyranyl (THP) group for the hydroxy group, and acetylation reaction (Non-Patent Literature 2).However, the process described in ...

HIGHLY UNSATURATED FATTY ACID OR HIGHLY UNSATURATED FATTY ACID ETHYL ESTER WITH REDUCED ENVIRONMENTAL POLLUTANTS, AND METHOD FOR PRODUCING SAME

A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester that has been produced using as a feedstock oil a fat or oil that contains highly unsaturated fatty acids as constituent fatty acids and which has been reduced in the contents of environmental pollutants, wherein among the dioxins contained, polychlorinated dibenzoparadioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) are contained in amounts of less than 0.05 pg-TEQ/g and coplanar PCBs (Co-PCBs) in amounts of less than 0.03 pg-TEQ/g. Also disclosed is a method for producing the highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester by the steps of removing free fatty acids and environmental pollutants by thin-film distillation from a feedstock oil, ethyl esterifying the resulting fat or oil, and refining the same by rectification and column chromatography. 1. A composition comprising a highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester which has been produced using as a feedstock oil or fat that contains (i) the highly unsaturated fatty acid as a constituent fatty acid , and (ii) a brominated flame retardant ,wherein the composition comprises a brominated flame retardant, and wherein the amount of the brominated flame retardant has been reduced to such a level that the amount of BDE-47 is less than 0.18 ng/g, the amount of BDE-100 is less than 0.03 ng/g, the amount of BDE-49 is less than 0.05 ng/g, or the amount of BDE-99 is less than 0.05 ng/g,wherein the concentration of highly unsaturated fatty acids in the sum of fatty acids in the composition is at least 80 area %.2. The composition according to claim 1 , wherein the concentration of highly unsaturated fatty acids in the sum of fatty acids in the composition is at least 85 area % claim 1 , at least 90 area % claim 1 , at least 95 area % claim 1 , or at least 96 area %.3. The composition according to claim 1 , wherein the fat or oil is fish oil claim 1 , krill oil claim 1 , marine ...

Systems and methods for production of mixed fatty esters

Disclosed herein are various embodiments regarding the production of fatty acid methyl esters. Disclosed herein are various embodiments regarding the use of methanol compositions for the production of fatty esters.

PLANT OIL-BASED MATERIALS

Plant oil-based compounds are provided which possess both low viscosity and high reactive functionality. These compounds are useful in coating and composite applications, as well as related methods. Exemplary compounds can be produced by transesterification of a plant oil triglyceride with a nucleophile reactant, such as a vinyl-functional alcohol, to yield reactive fatty acid-containing monomers. 2. The compound of claim 1 , wherein the fatty acid residue is from a plant oil triglyceride.3. The compound of claim 1 , wherein Ris allyl.4. The compound of claim 2 , wherein the plant oil is selected from the group consisting of soybean oil claim 2 , linseed oil claim 2 , sunflower oil claim 2 , safflower oil claim 2 , canola oil claim 2 , corn oil claim 2 , cashew nut oil claim 2 , olive oil claim 2 , peanut oil claim 2 , palm oil claim 2 , sesame oil claim 2 , cottonseed oil claim 2 , rapeseed oil claim 2 , walnut oil claim 2 , almond oil and coconut oil.5. The compound of claim 4 , wherein the oil is soybean oil.6. The compound of claim 1 , wherein at least one of Rand Rcontains at least one functionality selected from the group consisting of epoxide claim 1 , acrylate claim 1 , methacrylate claim 1 , hydroxyl claim 1 , and cyclic carbonate.7. A composition comprising a plurality of compounds of .8. The composition of claim 7 , wherein the plant oil is soybean oil claim 7 , and wherein for each of the plurality of compounds claim 7 , Ris a fatty acid residue independently selected from a linolenic acid claim 7 , a linoleic acid claim 7 , an oleic acid claim 7 , a stearic acid claim 7 , and a palmitic acid.9. A curable composition comprising at least one compound of .10. The curable composition of comprising a reactive diluent comprising the compound of .12. The method of claim 11 , wherein the nucleophilic reactant is monovalent.13. The method of claim 11 , wherein the nucleophile reactant is an alcohol claim 11 , thiol or amine.14. A polymer or copolymer comprising ...

LIPID COMPOSITIONS COMPRISING TRIACYLGLYCEROL WITH LONG-CHAIN POLYUNSATURATED FATTY ACIDS AT THE SN-2 POSITION

The present invention relates to lipid comprising docosapentaenoic acid and/or docosahexaenoic acid preferentially esterified at the sn-2 position of triacylglycerol, and processes for producing and using the lipid. 112-. (canceled)13BrassicaBrassicaBrassicaBrassica. Extracted sp. seedoil comprising a total fatty acid content which comprises fatty acids in an esterified form , the fatty acids comprising palmitic acid and C22 polyunsaturated fatty acid which comprises docosapentaenoic acid (DPA) and/or docosahexaenoic acid (DHA) , and the fatty acids optionally comprising myristic acid (C14:0) , wherein at least 35% of the DPA and/or DHA esterified in triacylglycerol (TAG) in the extracted sp. seedoil is esterified at the sn-2 position of the TAG , wherein a level of palmitic acid between 2% and 16% is present in the total fatty acid content of the extracted sp. seedoil , and wherein myristic acid , if present , is present at a level of less than 1% of the total fatty acid content of the extracted sp. seedoil.14Brassica. The extracted sp. seedoil of which has one or more of the following featuresi) the fatty acids further comprise one or more or all of oleic acid, ω6 fatty acids which comprise linoleic acid (LA), ω3 fatty acids which comprise α-linolenic acid (ALA) and optionally one or more or all of stearidonic acid (SDA), eicosapentaenoic acid (EPA), and eicosatetraenoic acid (ETA),{'i': 'Brassica', 'ii) at least 40% of the DPA and/or DHA esterified in TAG in the extracted sp. seedoil is esterified at the sn-2 position of the TAG,'}{'i': Brassica', 'Brassica, 'iii) the extracted sp. seedoil comprises a TAG content of at least 90% by weight of the extracted sp. seedoil, and'}{'i': 'Brassica', 'iv) a level of DPA and/or DHA of between 1% and 35% is present in the total fatty acid content of the extracted sp. seedoil.'}15BrassicaBrassica. The extracted sp. seedoil of claim 14 , wherein the level of DPA and/or DHA in the total fatty acid content of the extracted sp. ...

IMPROVED PROCESS FOR THE SELECTIVE HYDROGENATION OF VEGETABLE OILS

Process for the catalytic hydrogenation of vegetable oils wherein the oil is placed in contact with molecular hydrogen in the presence of a metal catalyst, and the process is performed in the absence of water or in the presence of a quantity of water equal to or less than 5:1 with respect to the weight of the metal catalyst and at a temperature equal to or less than 50° C. 1. A process for the catalytic hydrogenation of vegetable oils wherein the oil is placed in contact with molecular hydrogen in the presence of a metal catalyst , wherein said process is performed in the absence of water or in the presence of a quantity of water equal to or less than 5:1 with respect to the weight of the metal catalyst and at a temperature from 18 to 3° C.2. The process according to claim 1 , wherein said metal catalyst is selected from nickel claim 1 , platinum claim 1 , palladium claim 1 , osmium claim 1 , iridium claim 1 , copper claim 1 , iron claim 1 , rhodium claim 1 , ruthenium claim 1 , molybdenum claim 1 , tungsten and mixtures thereof.3. The process according to claim 2 , wherein said metal catalyst comprises metallic Palladium.4. A process according to claim 3 , wherein the hydrogenation is performed in the presence of 20 mg/kg-500 mg/kg of metallic Palladium with respect to the vegetable oil.5. The process according to claim 3 , wherein said metal catalyst comprises 0.1-5% by weight of metallic Palladium.6. The process according to claim 1 , wherein said metal catalyst is supported.7. The process according to claim 6 , wherein the support of said metal catalyst is selected from alumina claim 6 , carbon claim 6 , CeO claim 6 , ZrO claim 6 , CrO claim 6 , TiO claim 6 , MgO claim 6 , silica claim 6 , inorganic-organic sol-gel matrices claim 6 , polycrystalline oxide substrates claim 6 , amorphous carbon claim 6 , zeolites claim 6 , aluminosilicates claim 6 , alkaline earth carbonates such as magnesium carbonate claim 6 , calcium carbonate or barium carbonate claim 6 , ...

Novel composition of 7,9-dodecadienyl-1-acetate isomers and process for production thereof

The present invention relates to a process for preparing a mixture M1 of enol phosphate isomers devoid of (E,E) isomer and comprising at least 98% of (E,Z) isomer, at least 0.1% of (Z,Z) isomer and at least 0.1% of (Z,E) isomer, comprising bringing a mixture of isomers of said enol phosphate comprising a detectable amount of (E,E) isomer into contact with a hydrolysable dienophile in an organic solvent, followed by base hydrolysis of the medium obtained and elimination of the adduct formed, in order to obtain the mixture M1 devoid of (E,E) isomer.

New Uses of Lipophenolic Compounds

The present invention relates to compound of formula (I): wherein R is O—R 3 or R 1 and R 2 are identical or different and are each independently H, (C 1 -C 6 )alkyl, —CO—(C 1 -C 21 )alkyl or —CO—(C 11 -C 21 )alkenyl group, provided that at least one of R 1 or R 2 is H or (C 1 -C 6 )alkyl, R 3 is a —CO—(C 11 -C 21 )alkyl or —CO—(C 11 -C 21 )alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

MOLECULAR HOST FRAMEWORKS AND METHODS OF MAKING AND USING SAME

Crystalline molecular framework:small molecule compounds. The molecular framework is formed from guanidinium cations and organosulfonate anions and the guanidinium cations and organosulfonate anions are associated via one or more hydrogen bond. The small molecule(s) is/are encapsulated by the molecular framework. Methods for making crystalline molecular framework:small molecule compounds may include combining guanidinium cations, organosulfonate anions, and small molecules in a single step. The crystalline molecular framework:small molecule compounds can be used to determine the structure of the small molecule(s). 1. A crystalline molecular framework:small molecule compound comprising a molecular framework and one or more small molecules , wherein the molecular framework comprises a plurality of guanidinium cations and a plurality of organosulfonate anions , wherein the guanidinium cations and organosulfonate anions are associated via one or more hydrogen bond and the small molecule(s) is/are encapsulated by the molecular framework.2. The compound of claim 1 , wherein the plurality of organosulfonate anions is chosen from organomonosulfonate anions and organopolysulfonate anions.3. The compound of claim 2 , wherein the organopolysulfonates anions are chosen from organodisulfonates anions claim 2 , organotrisulfonates anions claim 2 , organotetrasulfonates anions claim 2 , and organopentasulfonate anions.4. The compound of claim 1 , wherein the compound is a single crystal.5. The compound of claim 1 , wherein the compound comprises one or more crystalline domain having at least one dimension of 100 nm to 200 μm.6. The compound of claim 1 , wherein each small molecule is a hydrocarbon.7. The compound of claim 1 , wherein the molecular framework does not comprise a metal and/or the small molecule does not comprise a metal atom or metal ion.8. The compound of claim 1 , wherein at least one small molecule or all of the small molecules has/have one or more stereocenters.9 ...

Free polyunsaturated fatty acid-containing composition and manufacturing method therefor

The present disclosure is: a free polyunsaturated fatty acid-containing composition, which comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, the content being at least 80.0% of the fatty acids in the composition, and satisfies at least one selected from a group consisting of conditions (1) and (2): (1) the content of conjugated unsaturated fatty acid is 1.0% or less of the fatty acids in the composition, and (2) the Gardner color is less than 3+; and a manufacturing method for the free polyunsaturated fatty acid-containing composition comprising the preparation of a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms, and hydrolysis of a reaction solution containing the prepared raw material composition, a lower alcohol, water and an alkali catalyst at a temperature of 10° C. or lower.

Mehod for the manufacture of a sorbic acid-based polymer network.

The present invention relates to a method for the manufacture of a polymer network comprising: a) reacting a glycidylether with one or more compounds comprising a sorbic acid-based moiety and obtaining a product having a predetermined viscosity; and c) polymerizing the product obtained in the preceding step into a polymer network. Further, the present invention relates to the manufactured polymer network and to a composite material comprising the polymer network. Furthermore, the present invention relates to adhesives and coating materials comprising said polymer network.

Method for the manufacture of a sorbic acid-based polymer network

The present invention relates to a method for the manufacture of a polymer network comprising: a) reacting a glycidylether with one or more compounds comprising a sorbic acid-based moiety and obtaining a product having a predetermined viscosity; and c) polymerizing the product obtained in the preceding step into a polymer network. Further, the present invention relates to the manufactured polymer network and to a composite material comprising the polymer network. Furthermore, the present invention relates to adhesives and coating materials comprising said polymer network.

올레핀 복분해 반응용 원료 정제를 위한 금속 입자 혼합물의 재생방법

본 발명은 올레핀 복분해 반응용 원료 정제를 위한 금속 입자 혼합물의 재생방법에 관한 것으로서, 올레핀 복분해 반응원료로 사용되는 천연오일, 오일 유도체 등의 원료로부터 촉매독 유발 물질 및 불순물을 흡수 및 제거한 금속 입자 혼합물을 재생하여 재사용할 수 있도록 하는 올레핀 복분해 반응용 원료 정제를 위한 금속 입자 혼합물의 재생방법 및 이를 이용한 올레핀 복분해 반응용 원료 정제 방법에 관한 것이다.

Plant extract composition for forming a protective coating

New class of cationic lipids for transporting active agents into cells

The subject of the present invention is the development of a new family of cationic lipids and the use thereof as vectors for in vitro , ex vivo and in vivo delivery of biologically active agents.

Adamantyl group-containing epoxy-modified (meth)acrylate and resin composition containing the same

本发明提供可以获得透明性、(长期)耐光性等光学特性、耐热性和良好的机械物性的含有金刚烷基的环氧改性(甲基)丙烯酸酯以及含有该化合物的树脂组合物。例如，是下述通式(I)所示的含有金刚烷基的环氧改性(甲基)丙烯酸酯以及含有该化合物的树脂组合物。式中，R 1 表示氢原子或甲基，R 2 表示卤素原子或可含有杂原子的脂族烃基。多个R 2 可以相同或不同。m为0～4的整数，n为0以上的整数。

Aryl derivatives of curcumin, demethoxycurcumin, bisdemethoxycurcumin or curcuminisoxazolide and their use as animal feed additives

本发明涉及姜黄素、去甲氧基姜黄素和二去甲氧基姜黄素的酰基衍生物和姜黄素异噁唑物作为用于改善动物机能的动物饲料组分或饲料添加剂的用途，新型的酰基衍生物本身以及含有上述衍生物的相应的动物饲料或饲料添加剂。

Methods of treating ear infections

Methods of treating and/or preventing otitis media in a subject are provided. Methods of treating and/or preventing otitis externa are also provided.

Polyol esters of metathesized fatty acids and uses thereof

Purification method of feedstock for the olefin metathesis

본 발명은 올레핀 복분해 반응용 원료를 금속 입자 혼합물과 접촉시킴으로써, 올레핀 복분해 반응용 원료내 촉매 유독 불순물을 고도로 제거함으로 복분해 촉매의 반응활성을 최대한 증가시키는 올레핀 복분해 반응용 원료의 정제 방법으로서, 망간, 철, 코발트, 니켈 중 선택된 둘 이상의 전이금속을 비담지 혹은 다공성 물질에 담지하여 제조한 금속 입자 혼합물을 사용한다.

Presentation of bioactives

It is used to form the composition of plant extracts of protective coating

本文描述了从含角质的植物物质制备角质‑衍生的单体、寡聚体或它们的组合的方法。所述方法可以包括在升高的温度和压强在溶剂中加热角质‑衍生的植物物质。在某些优选的实施方案中，所述方法可以在不使用另外的酸性或碱性物质的情况下进行。

Novel compounds isolated from Cervus nippon and pharmaceutical use thereof

본 발명은 하기 화학식 1 내지 4로 표시되는 화합물에서 선택되는 1종 이상을 유효성분으로 하는, 염증성 질환, 백혈구 감소증 또는 호중구 감소증의 예방 또는 치료용 약학적 조성물 및 이의 합성 방법을 제공한다. [화학식 1] [화학식 2] [화학식 3] [화학식 4] The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory disease, leukopenia or neutropenia, and a method for synthesizing the same, comprising at least one selected from the compounds represented by the following Chemical Formulas 1 to 4 as an active ingredient. [Formula 1] [Formula 2] [Formula 3] [Formula 4]

Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator.

La presente invención se refiere a co-cristales que comprenden N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquin olino-3-carboxamida (Compuesto 1) y un co-formador, y a métodos para su preparación. La presente invención se refiere además a composiciones farmacéuticas que comprenden las formas de co-cristal, así como a métodos de tratamiento con las mismas y kits.

Aqueous compositions comprising 6-undecanol-esters

The invention relates to aqueous compositions comprising 6-undecanol-esters and methods for producing 6-undecanol-esters, as well as the use of 6-undecanol-esters in cosmetic applications.

perfume precursor

【課題】保存安定性、特に水系製品中での安定性に優れ、長期間に亘り、香料を徐放することが可能な香料前駆体、この製造方法、これを用いた賦香方法、及びこれを含有する香料組成物、並びにこの香料組成物を含有する繊維処理剤、化粧料、毛髪化粧料、及び洗浄剤を提供する。【解決手段】フェノール構造又はヒドロキシ−４−ピロン構造を有する香料と、炭素数８以上、１８以下の脂肪族モノカルボン酸とのエステルからなる香料前駆体。【選択図】なし

Lipid comprising docosapentaenoic acid

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.

Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the sn-2 position

The present invention relates to lipid comprising docosapentaenoic acid and/or docosahexaenoic acid preferentially esterified at the sn-2 position of triacylglycerol, and processes for producing and using the lipid.

Lipid comprising long chain polyunsaturated fatty acids

The present invention relates to extracted plant lipid or microbial lipid comprising docosahexaenoic acid, and/or docosapentaenoic acid, and processes for producing the extracted lipid.

Lipid comprising docosapentaenoic acid

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.

Lipid comprising long chain polyunsaturated fatty acids

The present invention relates to extracted plant lipid or microbial lipid comprising docosahexaenoic acid, and/or docosapentaenoic acid, and processes for producing the extracted lipid.

Lipid comprising long chain polyunsaturated fatty acids

The present invention relates to extracted plant lipid or microbial lipid comprising docosahexaenoic acid, and/or docosapentaenoic acid, and processes for producing the extracted lipid.

Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the SN-2 position

The present invention relates to lipid comprising docosapentaenoic acid and/or docosahexaenoic acid preferentially esterified at the sn-2 position of triacylglycerol, and processes for producing and using the lipid.

Lipid comprising long chain polyunsaturated fatty acids

본 발명은 도코사헥사에노산(DHA)를 포함하는 추출된 식물 지질로 상기 추출된 지질의 전체 지방산 함량 중 DHA의 수준이 20.1% 내지 30% 또는 20.1% 내지 35%인 추출된 식물 지질에 관한 것이다. 본 발명은 또한 도코사펜타에노산(DPA)을 포함하는 식물 및/또는 미생물 지질로서 상기 추출된 지질의 전체 지방산 함량 중 DPA의 수준이 7% 내지 35%인 식물 및/또는 미생물 지질 및 상기 추출된 지질의 제조방법에 관한 것이다. The present invention relates to an extracted plant lipid comprising docosahexaenoic acid (DHA), wherein the level of DHA in the total fatty acid content of the extracted lipid is 20.1% to 30% or 20.1% to 35% will be. The present invention also relates to a plant and/or microbial lipid comprising docosapentaenoic acid (DPA), wherein the level of DPA in the total fatty acid content of the extracted lipid is 7% to 35%, and the extract It relates to a method for producing a lipid.

Lipid comprising docosapentaenoic acid

본 발명은 도코사펜타에노산을 포함하는 추출된 식물 지질 또는 미생물 지질, 및 추출된 지질의 제조 방법에 관한 것이다.

Polyol esters of metathesized fatty acids and uses thereof

总的来说，本文中公开了易位脂肪酸的多元醇酯。还公开了使用这样的化合物例如作为清洁剂、溶剂以及油漆和涂料用的聚结剂的方法。

Highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester with reduced environmental pollutants, and method for producing same

고도 불포화 지방산을 구성 지방산으로서 함유하는 유지를 원료유로 하여 제조되고, 환경 오염 물질의 함유량이 저감된, 고도 불포화 지방산 또는 고도 불포화 지방산의 에틸에스테르로서, 함유되는 다이옥신류 중, 폴리염화디벤조파라다이옥신 (PCDD) 및 폴리염화디벤조푸란 (PCDF) 의 함유량이 0.05 pg-TEQ/g 미만, 코플레이너 PCB (Co-PCB) 가 0.03 pg-TEQ/g 미만인 고도 불포화 지방산 또는 고도 불포화 지방산의 에틸에스테르 및 그 제조 방법으로서, 원료유로부터, 박막 증류에 의해 유리 지방산 및 환경 오염 물질을 제거하고, 얻어진 유지를 에틸에스테르화하고, 정류 및 칼럼 크로마토그래피에 의해 정제를 실시하는 방법.

Production and purification of esters of polyunsaturated fatty acids

The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that in-clude reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-con-taining composition that has not been conventionally processed. The reacted composition can be further processed by distillation.

Process for preparing derivatives of 3,7,11-trimethyl-2,4-dodecadienic acid

3,7,11-trimethyl-2,4-dodecadienoates of the general formula /I/ <IMAGE> wherein R<1> represents hydrogen or an alkoxy group, Z<1> represents hydrogen, or R<1> and Z<1> together form a double bond, Z<2> and Z<3> each represent hydrogen or together form an ethylene group, R<2> and R<3> each denote an alkyl group, provided that when Z<2> and Z<3> form an ethylene group, R<1> is hydrogen, R<2> is methyl and R<3> is ethyl, are prepared by reacting a compound of the general formula /II/ <IMAGE> wherein R<1>, Z<1>, Z<2>, Z<3> and R<3> have the above specified meanings, and Q represents a group of the general formula /IIIB/ -COR /IIIB/ wherein R stands for an alkyl, phenyl or phenyl-/lower alkyl/ group, and with a compound of the general formula /VI/ Li-Cu/R<2>/2 /VI/ wherein R<2> has the above defined meaning. The advantage of the process is that it consists of less reaction steps than the known methods and can be used also on an industrial scale. The compounds of formula /I/ are insect growth regulators and can be used to advantage in plant protection. The intermediates of formula /II/ are new.

Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof

There are provided various compositions comprising monoglyceride(s), diglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.